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ABSTRACT 
 
The pharmacological development of non-steroidal contraceptives has yet to be 
achieved. Arresting oocyte maturation without blocking ovulation has been 
evaluated using different inhibitors of the phosphodiesterase 3A (PDE3A). 
Unfortunately, PDE3A is also expressed in the heart and blood vessels, and 
inhibition of PDE3A in oocytes can produce cardiovascular side effects. We 
reviewed the literature on available PDE3 inhibitors and selected cilostazol 
(CLZ), which is an FDA approved therapeutic. CLZ has the ability to decrease 
cellular adenosine uptake and consequently antagonizes side effects of PDE3A 
inhibition in vital organs. CLZ inhibited oocyte meiotic maturation in vitro. CLZ 
has more degenerative impact on arrested oocytes than matured oocytes, 
indicating that prolonged meiotic arrest of oocytes is harmful. Administration of 
CLZ any time from 9h before the ovulatory stimulus to 4h after the stimulus 
resulted in ovulation of immature oocytes. Controlling CLZ dose, time of CLZ 
administration, and time of oocyte collection resulted in ovulation of oocytes at 
different meiotic stages. Oral administrations of CLZ in naturally cycling mice 
were also observed to block pregnancy whereas remating of those previously 
treated females resulted in normal offspring and litter sizes. Therefore, CLZ does 
not only have a wide margin of contraception but also is reversible.  
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Ovulated immature oocytes were observed to have higher rates of 
advanced chromatin configuration and cortical granule distribution, normal 
spindle and chromosomal organization, maturation, and in vitro fertilization (IVF) 
than ovarian immature oocytes. Ovulated metaphase I oocytes that were 
matured in vitro or in vivo had higher IVF rates than ovulated mature oocytes. 
Ovulated germinal vesicle (GV) oocytes that were in vitro matured also showed 
higher IVF rates but when in vivo matured, they had lower IVF rates than 
ovulated mature oocytes because of the high degeneration and low fertilization 
rates associated with in vivo maturation of GV oocytes. 
In summary, CLZ merits further evaluation as a non-steroidal 
contraceptive and is capable of producing oocytes of various meiotic stages with 
advanced developmental features. 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
In spite billions of dollars spent on contraceptive development, there are still 
pockets of overpopulation all over the world. According to the international data 
base of the US census bureau, it is believed that the highest populated country 
will be shifted from China to India by 2050. While it required 123 years (1804-
1927) for the population to produce the 2nd billion, it took 33 years to produce 
the third billion (from 1927 to 1960) and then only 12-14 years to produce one 
billion after 1960. The current world population reached seven billion on October 
31st, 2011, and is believed to project to 10.1 or 15.8 billion in 2100 when medium 
or high projection variants are referenced, respectively (United Nations 
Population Division 2002 and 2011). This intense population growth threatens 
the limited natural resources of food and fresh water on earth to sustain this 
massive population increase. This threat is not only haunting increasingly 
wealthy third-world countries but is also threatening industrialized countries. 
Numerous factors encourage development of more efficient, non-invasive, safe, 
cheaper, and convenient birth control. Among those factors are environmental 
problems such as global warming and desertification, pollution such as the 3 
months oil flow disaster in Gulf of Mexico in 2010 and the radioactive materials 
release accident of the Fukushima Nuclear Power Plant after the Tsunami in 
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Japan in 2011, population explosion of feral dogs, cats, and hogs that threaten 
livestock and crops, and political conflicts.  
During the 1920s, an Austrian scientist, Ludwig Haberlandt (1885 -1932), 
reported that administration of ovarian extracts in experimental animals 
produced temporal sterility. Haberlandt successfully analyzed some previous 
observations, which linked the development of the corpus luteum to lack of 
ovulation during pregnancy, into the concept of oral contraceptive pills (Djerassi 
2009; Goldzieher and Rudel 1974; Haberlandt 2009; Muller-Jahncke 1988). 
Currently, there are 2 types of oral contraceptives; the combined pill 
(combinations of an oestrogen, which is basically ethinyl estradiol and 
progestogen [synthetic progesterone]) and the progestogen only pill. The 
pharmacological mechanism of these pills uses the negative feedback loops of 
estrogen and progesterone on follicle stimulating hormone (FSH) and luteinizing 
hormone (LH) release, respectively (Berne et al. 2004; Odell and Molitch 1974; 
Kim and Wasik 2011). Studies have found that the current steroidal 
contraceptive medications precipitate side effects such as venous and arterial 
thromboembolism, hypertension, ischemic stroke. These medications were also 
reported to associate with breast cancer (Atthobari et al. 2007; Beaber et al. 
2012; Blanco-Molina et al. 2012; Hickson et al. 2011; Iatrakis et al. 2011; Tanis 
et al. 2001; White et al. 1994).  
In 1934, Pincus and Enzmann stated that “maturation of the ovum can be 
obtained simply by isolating it from the normal follicular environment” (Pincus 
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and Enzmann 1934). An inhibitory role for 3'-5'-cyclic adenosine monophosphate  
(cAMP) on spontaneous maturation was suggested in 1974 by Cho and 
coworkers after observing in vitro inhibition of oocyte meiotic maturation caused 
by dibutyryl cAMP and theophylline (Cho et al. 1974). The Phosphodiesterase 
3A (PDE3A) hydrolyzes intraoocyte-cAMP and triggers meiotic maturation. 
Wiersma and coworkers successfully blocked pregnancy when they 
administered some PDE3 inhibitors (PDE3-Is) in superovulated and naturally 
cycling rodents (Wiersma et al. 1998). Similar results were obtained with non-
human primates (Jeffrey et al. 2010; Jensen et al. 2005 and 2008). 
Unfortunately, an adverse effect of tachycardia was observed in both species 
(Jeffrey et al. 2010; Wiersma et al. 1998). Inhibition of the PDE3A enzyme in 
oocytes is believed to inhibit the same enzyme in the heart, vascular smooth 
muscles, and platelets. No further studies using this novel approach of targeting 
the final maturation phase of oocytes without interfering with the hormonal profile 
and ovulation were conducted in vivo. 
In this study, we considered all available PDE3-Is and selected cilostazol 
(CLZ) that appears to be a weak (based on IC50) and safe compound in 
comparison to other PDE3-Is. CLZ was reported to inhibit both cellular PDE3A 
and cellular uptake of adenosine. Inhibition of cellular adenosine uptake is 
believed to counterbalance some of the cardiovascular side effects that appear 
when other PDE3-Is are administered (Liu et al. 2000 and 2001). Moreover, CLZ 
is an FDA (pletal®) approved therapeutic agent that is prescribed to treat people 
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with intermittent claudication disease, a state that is characterized by lower limb 
pain while walking. Interestingly, CLZ has not been evaluated for its ability to 
inhibit oocyte maturation except for the manufacturer studies that found that CLZ 
does not impair fertility in rats using their methods (Otsuka America 
Pharmaceutical Inc. 2007). 
Two objectives in the current study were evaluated. These are 1) CZL 
ability to inhibit fertility as a non-steroidal contraceptive agent 2) CLZ ability to 
improve fertility through improving oocyte quality and fertility). Therefore, 
experiments were conducted to evaluate CLZ capability of inhibiting oocyte 
maturation in vitro and in vivo, define the effect of different times of oral 
administration of CLZ on oocyte meiotic maturation in vivo, test the ability of the 
in vivo arrested oocytes to undergo maturation in vitro or in vitro and in vitro 
fertilization (IVF), synchronize meiotic and cytoplasmic maturation of oocytes, 
and synchronize progression of meiotic events among oocytes. 
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CHAPTER II 
IN VITRO EVALUATION OF A PHOSPHODIESTERASE III INHIBITOR, 
CILOSTAZOL, ON MOUSE OOCYTE MEIOTIC  
 MATURATION AND MORPHOLOGY 
 
Overview 
Cilostazol has not been evaluated as an oocyte PDE3A inhibitor. The compound 
is FDA approved for patients with intermittent claudication. In order to study the 
inhibitory effects of CLZ on oocyte maturation, antral oocytes were retrieved 
from hyperstimulated mice and denuded before allocating to 10 different CLZ 
concentrations (0.00, 0.264, 0.528, 1.057, 2.114, 4.229, 8.458, 16.916, 33.832, 
and 67.664µM). Subsequently, the oocytes were assessed for maturational and 
morphological status after 24 and 48h of incubation. CLZ at concentrations of 
1.057-67.664µM (24h) and concentrations of 1.057-8.458 µM (48h) arrested 
oocytes at the germinal vesicle (GV) stage when compared to other 
concentrations (P< 0.0001). A considerable selective degenerative impact of 
CLZ on GV arrested oocytes was observed in 33.832 - 67.664µM (24h) and 
2.114- 67.664µM (48h) when compared to other tested CLZ concentrations 
(P<0.05 and P<0.0001, respectively). The degenerative pattern was analyzed 
and vacuolated oocytes were found to be predominant at low and medium CLZ 
concentrations, while both vacuolated and fragmented oocyte types were 
observed at high CLZ concentrations. It is concluded that CLZ can block in vitro 
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oocyte meiotic maturation efficiently and that prolonged maintenance of 
denuded oocytes at the GV stage is harmful, since mainly GV arrested oocytes 
were sensitive to the degenerative impact of CLZ. Furthermore, this 
degeneration increased as the CLZ concentration and incubation time 
increased, suggesting a role for cAMP in this degeneration. Our study shows 
that CLZ has a dose dependent inhibitory effect on oocyte spontaneous 
maturation. 
 
Introduction 
Oocyte meiotic maturation occurs during the first meiotic reduction and it 
represents nuclear development from a fully grown, non-fertilizable, prophase I 
oocyte to a fertilizable metaphase II (MII) ovum. This meiotic division is 
accompanied by a characteristic morphological transformation from a meiotically 
immature oocyte with a germinal vesicle into a mature ovum with the first polar 
body. Interestingly, oocyte meiotic maturation can take place spontaneously in 
vitro upon oocyte isolation from its follicle or under the surge of LH in 
preovulatory follicles (Ayalon et al. 1972; Donahu 1968; Hutt 2007; Pincus and 
Enzmann 1935; Wassarman et al. 1976). The ability of mammalian oocytes to 
undergo this spontaneous maturation in vitro or a hormonally triggered 
maturation in vivo is mainly due to mechanical interruption or hormonal 
phosphorylation, respectively, and subsequent closure of numerous membrane 
gap junctions. This junctional system furnishes the follicular oocytes with meiotic 
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inhibitory signals such as cAMP and 3'-5'-cyclic guanosine monophosphate  
(cGMP). Oocytes are capable of synthesizing their own cAMP, but surrounding 
somatic cells are believed to provide high intraoocyte cAMP levels and to 
maintain a non-functional state of PDE3A in oocytes; the enzyme that controls 
meiotic maturation (Gilula 1978; Norris et al. 2008 and 2009; Sela-Abramovich 
et al. 2006 and 2008; Sherizly et al. 1988). Many investigators have utilized 
PDE3-Is in experiments of oocyte maturation in order to disclose the 
biochemical and molecular biological mechanisms that influence meiotic 
maturation. Also, PDE3-Is have been studied to develop non-steroidal 
contraceptives that target this final maturational phase “meiotic maturation” of 
oocytes in humans and animals. 
Strong evidence for the predominance of PDE3 on the regulation of 
oocyte meiotic maturation was furnished by Masciarelli et al. (2004). They found 
that PDE3A knockout mice were capable of ovulating GV oocytes that failed to 
undergo spontaneous maturation in vitro for up to 48h. Moreover, microinjection 
of PDE3 into GV arrested oocytes cultured in the presence of PDE-I overcame 
the inhibitory effect of PDE-I on meiotic maturation (Bornslaeger et al. 1986). 
Many PDE3-Is like cilostamide, Org 9935, milrinone, pimobendan, and 
trequinsin have been studied in numerous species and found to arrest oocyte 
meiosis at the GV stage by maintaining elevated oocyte cAMP concentrations 
(Bilodeau-Goeseels 2003; Grupen et al. 2006; Jensen et al. 2002; Nogueira et 
al. 2005a and b; Thomas et al. 2002; Wiersma et al. 1998).  
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Cilostazol is a PDE3A inhibitor that is prescribed for patients with 
intermittent claudication disease (Chapman and Goa 2003; Meru et al. 2006). 
Although the majority of the PDE3-Is have been used to arrest oocyte 
maturation, CLZ has not been evaluated. Interestingly, CLZ has an additional 
unique pharmacological mechanism over the rest of the PD3-Is in that it has the 
ability to decrease the cellular uptake of adenosine (Liu et al. 2000 and 2001; 
Sun et al. 2002). The latter effect is thought to be responsible for antagonizing 
the side effects that could appear when other PDE3-Is are administered to 
humans or other mammals, especially for long periods of time (Liu et al. 2000). 
The primary aim of this research was to evaluate the inhibitory effect of CLZ on 
oocyte meiotic maturation in vitro. This compound appears to be the safest of 
the PDE3-Is; thus it is a suitable candidate for studying inhibition of oocyte 
meiotic maturation in vivo and its potential as a non-steroidal contraceptive in 
humans and animals.  
 
Materials and methods 
Animals 
Swiss Webster albino mice, 4-6 weeks of age were purchased from Harlan 
Laboratories (Houston, TX) and housed in groups of 5-8 mice per cage in the 
Texas A&M University Laboratory Animal Facility. Mice were under controlled 
temperature (23°C) and light/dark (14/10 h) cycle. Food and water were 
provided ad libitum. The experiments were conducted in accordance with the 
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Animal Care Guidelines of the Institutional Animal Care and Use Committee of 
Texas A&M University.  
 
Reagents 
CLZ was purchased from LKT Laboratories, Inc, (St. Paul, MN, USA), Leibovitz’s 
L-15 Medium (1X), liquid, GIBCO® brand, was purchased from Invitrogen 
(Carlsbad, CA), and EmbryoMax® FHM, liquid, without phenol red was 
purchased from Millipore (Billerica, MA, USA). Pregnant mare serum 
gonadotropin (PMSG), hyaluronidase from bovine testes, and dimethyl sulfoxide 
(DMSO) were all purchased from Sigma Chemical Co. (St. Louis, MO). CLZ was 
dissolved in DMSO and diluted with overnight CO2 equilibrated FHM medium to 
make 10 CLZ concentrations: T1: 0.00 [control group], T2: 0.264, T3: 0.528, T4: 
1.057, T5: 2.114, T6: 4.229, T7: 8.458, T8: 16.916, T9: 33.832, and T10: 67.664 
µM CLZ. The highest DMSO concentration was at T10 (0.1%) while the 
minimum DMSO concentration was at T2 (0.003%). The control culture medium 
contained 0.1% DMSO to detect any possible effect that DMSO could have on 
oocyte meiotic maturation and/or morphology. 
 
Oocyte collection and incubation 
Female mice were injected i.p. with 5 IU of PMSG (0.1ml) to stimulate 
development of multiple follicles. Forty-seven to fifty hours later, the 
anesthetized animals were sacrificed by cervical dislocation and the ovaries 
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were collected in Leibovitz’s L-15 medium supplemented with 10% fetal bovine 
serum, 100 U/ml penicillin, and 100 µg/ml streptomycin. The antral follicles were 
punctured under a stereomicroscope (Nikon, SMZ 1500 model) using 30-gauge 
needles. Cumulus-enclosed oocytes (CEO) were denuded by placing the CEO 
in Leibovitz’s L-15 medium with 1% hyaluronidase for less than 5 minutes with 
mechanical manipulation. Denuded oocytes (DO) at the GV stages were washed 
in fresh Leibovitz’s L-15 medium to remove the hyaluronidase followed by 
another two washes in FHM medium before pooling and allocating to each of the 
CLZ test concentrations. The DO were incubated up to 48h at 37ºC with 5% CO2 
and in a humidified environment. The oocytes were scored at 24h and 48h of 
culture. No PDE-Is were used in the initial collection and washing steps to 
exclude any possibility of PDE3-I effects on meiotic maturation and morphology 
rather than that of CLZ. The isolation procedure from the time antral follicles 
were punctured to allocation into the treatment groups was approximately 15 
minutes per mouse.  
At the end of each incubation period, the oocytes were examined for their 
meiotic status by a stereomicroscope or inverted microscope (Olympus, IX71 
model) and classified as follows: 1) Oocytes showing a nuclear membrane and 
intact nucleolus were classified as meiotically arrested at the GV stage. 2) 
Oocytes showing no nuclear structures or envelopes were classified as having 
undergone germinal vesicle breakdown (GVBD). 3) Oocytes that had undergone 
GVBD but did not have a polar body were classified as metaphase I (MI). 4) 
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Oocytes that had no nuclear envelopes and with first polar bodies were 
classified as MII oocytes (Tsafriri and Kraicer 1972). Morphological appearance 
of oocytes, whether in GV, MI, or MII, was classified as follows: 1) Degenerated/ 
fragmented: coarse granular, non-homogeneous, and dark (brownish-blackish) 
cytoplasm; 2) Degenerated/ vacuolated: non-spherical and with or without large 
perivitelline space oocytes (irregular shape); 3) Non-degenerated oocytes: 
spherical in shape, with smooth granular and transparent cytoplasm. 
 
Statistical analysis 
Multiple linear correlations were used to determine the linear relationship 
between the treatments and different oocyte stages of meiotic maturation and 
normality. Correlation was also used to determine the relationship between 
different oocyte stages starting from T7 (24h) and T4 (48h). Those 
concentrations were found to represent the concentrations at which the biphasic 
effects of CLZ on GV type oocytes were shown. The Chi-square test was used 
to evaluate all other differences. Statistical differences were considered 
significant at the level of P<0.05 using SPSS 14.0 (SPSS Inc., Chicago, IL, 
USA). At least 3 oocyte replicates were used for each treatment. Each replicate 
represented oocytes from 3-5 female mice.  
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Results 
Twenty four hour incubation 
Oocytes arrested at the germinal vesicle stage 
Increasing CLZ concentrations linearly correlated with arresting 
spontaneous oocyte maturation at the GV stage (r=0.77, P<0.0001, Fig. 2.1). 
CLZ concentrations of T4-T10 were able to arrest more oocytes at the GV stage 
than the control and low CLZ concentrations of T2-3 (P<0.0001).The T4-10 
concentrations maintained more oocytes at the GV stage than the GVBD stage 
(P<0.0001).  Moreover, T6-8 concentrations were more effective in maintaining 
oocytes at the GV stage than T4-5 (P<0.0001), indicating a dose response 
pattern. The GV arresting effect was not consistent at every concentration as 
higher concentrations of T9-10 showed less GV arrested oocytes when 
compared to lower concentrations of CLZ of T6-8 (P<0.03) and T10 was not 
significantly different from T4-5 (P=0.06). To analyze this inability of high 
concentrations of CLZ to preclude spontaneous maturation at the GV stage, 
multiple correlation analysis revealed a negative linear relationship between 
arrested oocytes at GV and degenerated oocytes at concentrations T7-T10 (r=-
.0.781, P<0.0001). There was no significant correlation between oocytes that 
had undergone GVBD and degeneration (r=-0.082, P=0.64), indicating that the 
GV oocytes are the only oocytes that are liable to degenerate. This distinction of 
fewer oocytes arrested at the GV stage in high concentrations of CLZ was due 
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to the fact that those GV oocytes were degenerated and consequently classified 
as degenerated. 
 
 
Figure 2.1. Cilostazol effects on oocyte meiotic maturation and morphology after 24h. Immature 
oocytes from antral follicles of hyperstimulated mice were denuded and incubated with 10 
different CLZ concentrations and evaluated for their meiotic maturation and morphological 
normality after 24h. As CLZ concentrations were increased, more oocytes were arrested at 
germinal vesicle (GV) stage and less oocytes succeeded to undergo germinal vesicle breakdown 
(GVBD). At high CLZ concentrations, degeneration was noted targeting essentially the arrested 
oocytes at GV stage. T1, T2, T3, T4, T5, T6, T7, T8, T9, T10 were evaluated with numbers of 
oocyte corresponding to 450, 148, 152, 119, 100, 123, 118, 210, 130, and 122 oocytes. Data are 
presented as oocyte percent from the total number of scored oocytes at each treatment. Values 
with no common superscript within each treatment are significantly different at p<0.0001 except 
at b* and a superscripts with P<0.05 using Chi square test.  
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Oocytes that underwent germinal vesicle breakdown 
A negative correlation was identified between increasing concentrations 
of CLZ and oocytes that underwent GVBD (r=-0.88, P<0.0001, Fig. 2.1). More 
oocytes were prevented from undergoing GVBD with CLZ concentrations of T4-
10 (P<0.0001). The GVBD blocking effect was progressive along CLZ effective 
concentrations (T4-10) because T6-10 significantly reduced the GVBD oocytes 
more than T4-5 (P<0.0001, Fig. 2.1). Once CLZ was introduced to the control 
culture, the MII predominance over MI oocytes (P<0.0001, Fig. 2.2A) was lost.  
Moreover, concentrations of CLZ of T4-6 and T8-10 showed MI predominance 
over MII oocytes (P<0.05). A decline in MI oocytes along the different CLZ 
concentrations occurred at T6 through T10 in comparison to lower 
concentrations (P<0.005), while a significant reduction of the MII oocytes 
appeared at lower concentrations of T4 through T10 in comparison to control 
and T2-3 (P<0.0001). The effect of the MII oocyte reduction was progressive, as 
T6 through T10 exhibited less MII oocytes than T1-4 (P<0.03). 
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Figure 2.2. Metaphase I (MI) and metaphase II (MII) oocyte distribution after incubating 
immature oocytes with 10 different CLZ concentrations for 24h (A) and 48h (B). Once CLZ was 
introduced to the control medium, the significant predominance of MII over MI oocytes was lost. 
At the effective inhibitory concentrations of CLZ that start at T4, less MII oocytes were observed 
than MI oocytes. Data are presented as oocyte percent from the total number of scored oocytes 
of each treatment. Values with asterisk are significantly different within each treatment. *<0.05, 
**<0.01, ***<0.001, ****<0.00001 using Chi square test. T1, T2, T3, T4, T5, T6, T7, T8, T9, T10 
were evaluated with numbers of oocyte corresponding to 450, 148, 152, 119, 100, 123, 118, 
210, 130, and 122 oocytes.   
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Degenerated oocytes 
The weakest correlation was observed between the different 
concentrations of CLZ and oocyte degeneration (r=0.55, P<0.0001, Fig. 2.1). 
After 24 h of incubation, CLZ concentrations of T9-10 showed higher numbers of 
degenerated oocytes when compared to T1-8 (P<0.05). The degeneration also 
elevated in T8 when compared to T1-4 and T7 (P<0.01 and P<0.009, 
respectively). Moreover, concentrations of T9-10 showed higher numbers of 
degenerated oocytes than oocytes with GVBD (P<0.05), but less than GV 
arrested oocytes (P<0.0001). This degenerative effect of the CLZ concentration 
of T8-10 was also noted when incubated oocytes were assessed as normal or 
abnormal based upon the morphological appearance of the oocytes (Fig. 2.3A), 
regardless of the stage of meiotic maturation (P<0.01). The overall distribution 
for vacuolation/fragmentation in degenerated oocytes revealed an increase in 
both fragmented and vacuolated type oocytes at the high CLZ concentrations of 
T9-10 (P<0.05) and T8-10 (P<0.04), respectively, compared to other 
concentrations. The overall trend for these 2 forms of morphologically 
degenerated oocytes showed that the vacuolated type oocytes were the 
predominant form of degenerated oocytes at the low and medium concentrations 
of CLZ, whereas both types of degenerated oocytes occurred at the high 
concentrations (Fig. 2.4).  
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Figure 2.3. Degenerative impacts of different CLZ concentrations on oocyte morphology after 
24h (A) and 48h (B). More degenerated oocytes were observed at higher CLZ concentrations 
than lower concentrations. Data are presented as oocyte percent from the total number of 
scored oocytes. Values with no common superscripts along the different treatments of the same 
oocyte type are significantly different (P<0.05). 
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Figure 2.4. Degenerative impacts of different CLZ concentrations on oocyte morphology after 
24h and 48h incubation. Fragmented degenerated oocytes displayed coarse granular, non-
homogeneous, and dark (brownish-blackish) cytoplasm after incubating for 24 (A-B) and 48h (C) 
with16.916, 33.832, or 67.664 µM of CLZ, respectively. Vacuolated degenerated oocytes 
displayed non-spherical oocytes with or without a large perivitelline space after incubating for 24 
(D-E) and 48h (F-G) with 8.458, 16.916, 33.832, or 67.664µM of CLZ, respectively.  
Morphologically normal oocytes evoked spherical shape, with smooth granular and transparent 
cytoplasm at different meiotic maturational stages after incubating for 24 (H-I) and 48h (J-L) with 
0.264, 0.528, 0, 2.114, or 8.458µM of CLZ, respectively. 
 
 
 
 19 
 
Forty eight hour incubation 
Oocytes arrested at the germinal vesicle stage 
No correlation was detected between the concentrations of CLZ and GV 
arrested oocytes (r=0.065, p=0.57, Fig. 2.5) due to a biphasic trend of increasing 
concentrations of CLZ on GV arrested oocytes (inverted U shape). This was 
further analyzed by examining the possible correlation among GV, GVBD, and 
degeneration outcomes which showed a strong negative influence of 
degeneration on GV oocytes (r=-0.938, P<0.0001) and to a lesser extent on 
GVBD oocytes (r=-0.822, P<0.0001). Interestingly, both GV and GVBD oocytes 
were positively correlated with each other (r=0.6, P<0.0001); two states that are 
usually inversely proportional for in vitro culture systems. CLZ at concentrations 
of T4-T7 was able to arrest more oocytes at the germinal vesicle stage when 
compared to other concentrations (P<0.0001). This effect was not continuous as 
T8 showed more GV arrested oocytes than T9 (19.52 vs. 10%, P=0.002) and T9 
in turn was restraining more GV oocytes than T10 (10 vs. 1.6%, P=0.005). 
Collectively, these data indicate that the notable increase of degenerated 
oocytes was due to degeneration of GV and to less extent GVBD oocytes and 
consequently those oocytes were classifies as degenerated oocytes. This also 
means that the capability of CLZ to arrest oocyte meiotic maturation was 
constant up to 48 h and that it is the degeneration that was reducing the GV 
oocyte percentage.  
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Figure 2.5. Cilostazol effects on oocyte meiotic maturation and morphology after 48h. Immature 
oocytes from hyperstimulated mice were denuded and incubated with 10 different CLZ 
concentrations and evaluated for their meiotic maturation and morphological normality after 48h. 
As CLZ concentrations were increased, the arrested oocytes at germinal vesicle GV stage 
started to decrease due to degeneration. CLZ shows a sustained inhibitory effect and prevented 
oocytes from undergoing germinal vesicle breakdown (GVBD) up to 48h. CLZ concentrations of 
T1, T2, T3, T4, T5, T6, T7, T8, T9, and T10 were evaluated with numbers of oocyte 
corresponding to 450, 148, 152, 119, 100, 123, 118, 210, 130, and 122 oocytes. Data are 
presented as oocyte percent from the total number of scored oocytes at each treatment. Values 
with no common superscript within each treatment are significantly different at p<0.0001 except 
at *b and a superscripts with P<0.05 using Chi square test. 
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Oocytes that underwent germinal vesicle breakdown 
A negative linear correlation was observed between increasing CLZ 
concentrations and GVBD oocytes (r=-0.927, P<0.0001, Fig. 2.5). CLZ at 
concentrations of T4-T10 was able to reduce the spontaneous germinal vesicle 
breakdown when compared to the control group and to low CLZ concentrations 
of T2-3 (P<0.0001). Unlike the GV arresting effect of CLZ, the GVBD effect was 
continuous and as CLZ concentration increased, more oocytes were blocked 
from undergoing GVBD. The CLZ concentration of T6 prevented oocytes from 
undergoing GVBD in comparison to T4 (P<0.0001) while T10 prevented more 
oocytes from undergoing GVBD when compared with T7 (P=0.012). No 
comparative block was observed among T8, T9, and T10. Furthermore, scoring 
for GVBD oocytes revealed MI oocyte sovereignty from T4-10 in contrast to MII 
oocytes sovereignty in control and non-inhibitory concentrations (P<0.0001, Fig. 
2.2B). Additionally, extending the incubation time from 24 to 48 h did not result in 
significant increases in oocytes undergoing GVBD or first polar body emission 
(P>0.05). 
 
Degenerated oocytes 
Linear correlation was also present between increasing concentrations of 
CLZ and the increase in degenerated oocytes (r=0.874, P<0.0001, Fig. 2.5). 
Increases in the number of degenerated oocytes after 48 h of CLZ exposure 
began at T5 when compared to T1-4 (P<0.0001, Fig. 2.3A and 2.5) whereas 
 22 
 
scoring of the oocytes after 24 h of exposure showed T8 as the first 
concentration of CLZ to negatively impact oocytes (critical degenerative 
concentration). Furthermore, as the concentration of CLZ was increased beyond 
T5 for 48 h of exposure, the degenerative impact on oocytes was more vigorous. 
The CLZ concentration of T8 negatively impacted the morphology of oocytes 
when compared to T4-7 (P<0.0001), while treatments of T9 degenerated more 
oocytes than T8 (P<0.01) and T10 more than T9 (P=0.006). 
When degenerative changes based on morphological assessment of 
normal or abnormal oocytes were analyzed without considering the meiotic 
status (Fig. 2.3B), we found that T5-10 decreased the number of normally 
appearing oocytes when compared to T1-T4 (P<0.0001), indicating a harmful 
effect of increasing CLZ concentrations on oocyte morphology. Moreover, each 
treatment within this degenerative range reduced the proportion of non-
degenerated oocytes more than the previous treatment (P<0.01). As for 
fragmented and vacuolated degenerated oocytes (Fig. 2.3B), T5-10 showed 
more vacuolated degenerated oocytes when compared to control and T2-4 
(P<0.0001). Also, T7-8 and T10 showed higher numbers of vacuolated oocytes 
than other concentrations (P<0.0001). Fragmented oocytes increased at the last 
three concentrations (P<0.0001), with a peak at T9 that exceeded the 
vacuolated type oocytes (P<0.001). Extending the incubation period from 24 h to 
48 h did not change the expression of these degenerative forms as the 
vacuolated type oocytes were predominant from T1 through T8 (p<0.01), while 
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both degenerated forms were apparent at T8-10. Incubation up to 48 h with CLZ 
did not support further degenerative progression from vacuolation into 
fragmentation (Fig. 2.4).  
 
Discussion 
We show here for the first time that CLZ is able to block mouse oocyte meiotic 
maturation efficiently in an in vitro culture system at concentrations and 
efficiency that resemble other potent and well documented PDE3-I, such as 
cilostamide, Org 9935, and milrinone. It is hypothesized that inhibition of PDE3 
by cilostamide is 10 times greater than that of CLZ, since  the IC50 of 
cilostamide in platelets is 20nM and CLZ in vascular smooth muscle is 200nM 
(Bender and Beavo 2006; Tanaka et al. 1988). However, the present study has 
shown that 4.2 µM CLZ was able to arrest more than 85% of oocytes at the GV 
stage compared to a 100% arresting of oocytes at the GV stage by 1 or 5 µM 
cilostamide (Jee et al. 2009; Vanhoutte et al. 2008), or 89% of oocytes at the GV 
stage by 8.5 µM cilostamide (Coticchio et al. 2004) when mouse oocytes were 
treated for less than 24 h. It is worth noting that we used DO and not CEO, 
which were used in the above referenced studies. The information regarding the 
comparative efficiency between DO and CEO to undergo GVBD is contradictory. 
Mechanical isolation of the oocytes and denudation from other somatic follicular 
cells interrupt meiotic inhibitory communication between oocytes and follicular 
cells through the numerous gap junctions. Such interruption is believed to cut 
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the somatic compartment supply of inhibitory substances such as cAMP and 
cGMP, which are known to forestall the meiotic progression. Indeed gap junction 
interruption is believed to be a prerequisite to GVBD (Norris et al. 2008 and 
2009; Sela-Abramovich et al. 2006 and 2008; Sherizly et al. 1988). Moreover, 
follicular oocytes can maintain the GV stage even after mechanical isolation 
from the ovaries if gap junctions are still intact and functional (Nogueira et al. 
2005b). These data suggest that DO are free from the somatic meiotic inhibitory 
effects and are more liable to undergo GVBD than CEO. On the other hand, 
nuclear maturation rates were found to be higher when cumulus cells remained 
intact as opposed to being removed prior to in vitro maturation (Chang et al. 
2005; Goud et al. 1998; Zhang et al. 1995). In vitro maturation of rat CEO 
shortened the time required for polar body emission by 2 h and increased the 
penetration rate and embryo competence more than DO matured in vitro 
(Vanderhyden and Armstrong 1989).  
The proportion of DO shown to undergo GVBD was higher (while the GV 
proportion was lower) than those in CEO treated using the same PDE3-I 
(Nogueira et al. 2005b; Shu et al. 2008; Tsafriri et al. 1996). This suggests that 
DO were more likely to undergo GVBD than the enclosed type oocytes.  Also, 
the overall preparation for these oocytes from the time of animal sacrifice until 
the beginning of incubation was approximately 15 minutes. Importantly, no 
oocyte meiotic maturational inhibitor was added to the culture medium during 
oocyte retrieval and preparation, demonstrating block of meiotic maturation was 
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due to CLZ. We suggest that these factors contributed to the lack of complete 
inhibition of meiotic maturation at the GVBD level, especially since no significant 
increase was observed in the number of MI and MII oocytes after 48h of 
incubation from that of 24h. This indicates that the initiation of GVBD may have 
already begun in some of the oocytes and that it was too late for CLZ to inhibit 
this process.   
Interestingly, CLZ is able to maintain a constant inhibitory action on 
oocyte maturation, an effect not usually observed with other PDE3-Is. In this 
regard, Bilsdeau-Goeseels (2003) reported that trequinsin at concentrations of 
10 and 50nM was unable to maintain its meiotic maturational inhibitory effect on 
bovine DO when the incubation period was extended from 7h to 22h. 
Furthermore, Shu et al. (2008) showed that 20µM cilostamide continuously 
lacked the inhibitory effect on GVBD of human CEO when meiosis was 
evaluated at different time points up to 48h. Conversely, the present study has 
showed a constant inhibitory effect of CLZ when the incubation period of mouse 
oocytes was prolonged from 24h to 48h.  
The concentrations of CLZ evaluated in this study are relevant to humans 
since these levels have been observed clinically in both healthy people and 
those with intermittent claudication disease who are taking CLZ (Bramer et al. 
1999). Single oral administration of 50, 100, or 200mg in normal healthy 
volunteers produced plasma concentrations of 411.03±83.5, 625.01±168, or 
806.15±238µg/L, respectively, while the steady state plasma concentration after 
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100mg oral administration, twice daily, for 12 days was 1223±432µg/L. These 
plasma concentrations are similar to our CLZ concentrations of T4-T6 that 
showed a significant reduction in GVBD and an increase in GV arrested mouse 
oocytes. This suggests that doses of 50, 100, and 200mg CLZ, which are the 
normal dosages for treatment of intermittent claudication, may have 
contraceptive effects in woman if the compound is capable of inducing the same 
inhibitory effect on human oocyte maturation in vivo.  At this time, however, 
there have been no reports of contraceptive effects in women who have taken 
CLZ therapeutically. It is possible, however, that most of the patients with 
intermittent claudication are past the normal reproductive age. 
Oocyte degeneration was elevated as CLZ concentrations were 
increased. Knowing that the majority of these degenerated oocytes were able to 
be scored and were in the GV stage explains the reduction in the capability of 
arresting oocytes at the GV stage at high CLZ concentrations in comparison with 
lower concentrations. This lack of oocyte meiotic inhibition at high 
concentrations was not due to GVBD development but was due to GV oocyte 
degeneration. These observations indicate that only GV arrested oocytes, not 
GVBD oocytes, were degenerated at 24h. At 48h, we noted a greater 
degeneration on GV oocytes and less degeneration on GVBD. If our scoring 
system was only looking for the two end points of GV and GVBD, and not for 
degeneration as well (especially, we were able to score many of these 
degenerated oocytes), such classification would have shown that more than 
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92% of GV oocytes were arrested, instead of the lower percent noted when the 
CLZ treatment of 67.6 µM was evaluated. This decline in the percent of GV 
arrested oocytes can be designated as a pseudo-decline. These data indicate 
that CLZ is not losing its efficacy as a PDE3 inhibitor and it is stable during long 
term incubation.  
An important point to be addressed whenever DO are cultured in vitro is 
the possibility of inducing compromised metabolic competence. Metabolic 
cooperativity and coupling is established between the oocytes and the follicular 
cells through delineated gap junctions (Heller et al. 1981; Pelland et al. 2009).  
Denuded oocytes are incapable of efficiently uptaking some essential nutrients, 
such as amino acids and adenosine triphosphate, from the culture medium when 
concentrations resemble those in plasma. The cumulus cells are thought to be 
controlled through oocyte paracrine factors to prompt them to uptake amino 
acids and supply the oocytes (Eppig et al. 2005). In this regard, specific amino 
acids and ribonucleosides are transferred into the oocyte through this metabolic 
coupling of cumulus cells (Colonna and Mangia 1983; Heller et al. 1981). 
Likewise, DO of optimum growth and developmental states could not continue 
48h without degeneration under this condition of low nutrition. On the other 
hand, the marked degeneration noted in our study was proportional to the 
concentrations of CLZ and only the GV arrested oocytes were significantly 
sensitive during the 24h incubation to this degenerative impact.  
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Few data are available on oocyte degeneration and toxicity after direct 
chemical exposures. Research on oocyte development has mainly focused on 
understanding oocyte metabolic and biologic functions, as well as on assisted 
reproductive technologies such as cloning, in vitro maturation, and fertilization. 
Cellular toxicity can be attributed to oxidative stress such as plasma membrane 
lipid peroxidation, immunological inflammation such as cytokine over release, 
cytogenetic damage such as DNA strand fragmentation, or others. Tamura et al. 
(2008) reported that human degenerated oocytes have high concentrations of 8-
hydroxy-2`-deoxyguanosine (a biomarker for oxidative stress), and that the 
addition of hydrogen peroxide significantly reduced the number of in vitro 
matured oocytes in a dose dependent manner. Interestingly, CLZ concentrations 
of 30-100µM similar to our tested concentrations have been shown to inhibit 
oxidative stress–induced premature senescence via activation of endothelial 
nitric oxide synthase (eNOS) in human umbilical vein endothelial cells (Ota et al. 
2008). On the other hand, eNOS knock-out mice showed more oocytes with 
atresia-related apoptosis relative to those in wild type mice (Jablonka-Shariff and 
Olson 1998). Human neuroblastoma and brain microvascular endothelial cells 
were found to augment metallothionein (MT), scavengers of reactive oxygen 
species (ROS), after exposure to 1-50µM CLZ in vitro (Suzuki et al. 2007). 
Furthermore, mRNA expression of antioxidant enzymes such as reduced 
glutathione (GSH), g-glutamyl-cysteine transferase (GCS), and superoxide 
dismutase (SOD) in mouse, bovine, and human oocytes have been confirmed 
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(El Mouatassim et al. 1999; Lonergan et al. 2003; Sugino 2005). GSH was 
shown to be proportionally correlated with fertilization rate and embryonic 
development, but did not affect the progression of meiotic maturation (De Matos 
et al. 2002 and 2003; Gasparrini et al. 2006; Zhou et al. 2010). With regard to 
CLZ, the compound restored GSH level in diabetic human and rat nephropathy, 
which protected against a pathological inflammatory burden produced by 
hyperglycemia induced-ROS (Lee et al. 2010). In regard to immunological 
inflammatory effects, the compound inhibited bacterial lipopolysaccharide (LPS) 
stimulated pro-inflammatory cytokine production in macrophages (at 30 and 
40µM) and rescued the mice from LPS-induced inflammation and mortality (Park 
et al. 2010).  
Although temporary nuclear arrest of human GV oocytes with 1µM of 
cilostamide for 24h  produced more oocytes with normal bipolar spindles and 
aligned chromosomes than non-arrested oocytes (Vanhoutte  et al. 2007), the in 
vitro matured oocytes in mice showed significantly greater DNA fragmentation 
than  in vivo-matured oocytes (Huang et al. 2008).  The magnitude of DNA 
damage (comet tail length) was greater for in vitro matured bovine oocytes than 
those treated with antioxidants (Mukherjee et al. 2010). Shin et al. (2004) 
showed that CLZ concentrations of 0.01-100µM inhibited DNA fragmentation 
and apoptosis of human umbilical vein endothelial cells cultured with remnant 
lipoprotein particles for 24 h. Hong et al. (2003 and 2006) showed a preventive 
effect of 0.1-10µM CLZ on the prominent DNA fragmentation of human brain 
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neuroblastoma cells treated with TNF-α for 24h. Lee et al. (2004) confirmed this 
neuroprotective effect of CLZ when the compound was administered orally to 
rats induced with cerebral ischemic injury, and demonstrated that the affected 
neurons showed a suppressed DNA fragmentation laddering feature and low 
apoptosis.  
Collectively, these data suggest that CLZ has cellular protective 
properties against ROS, inflammation, and DNA fragmentation. CLZ also 
restores the levels of MT, GSH, and eNOS. Moreover, relating oocyte 
degeneration to a lack of metabolic coupling upon denudation from other cells is 
not supported by our observation of a positive correlation between CLZ 
concentration and essential targeting of GV arrested oocytes. This information, 
along with our results, leads us to suggest that prolonged sustaining of oocytes 
at the GV stage is harmful. Persistent and cumulative high levels of cAMP could 
be responsible for this degenerative effect, as a majority of these degenerated 
oocytes were from the GV arrested oocyte pool. A continuously high intraoocyte 
cAMP level is suggested to be negatively correlated to oocyte quality and 
normality. The potency and duration of PDE3 inhibition and cAMP accumulation 
could be the reason for the contradictory results related to the beneficial effect of 
in vitro meiotic synchronization on oocyte competence, in vitro fertilization, and 
embryo development (Curnow et al. 2011; Jee et al. 2009). Further studies are 
required to gain insight as to the effects of cAMP levels on oocyte viability, 
competence, and developmental capacities. Also, potential toxic effects of CLZ 
 31 
 
on oocytes should be addressed. Studies are also needed to further understand 
the reason(s) of vacuolation and fragmentation of oocytes caused by different 
concentrations of the CLZ.  
 
Summary and conclusion 
• Cilostazol inhibits spontaneous oocyte maturation in vitro in mice. 
• The inhibitory concentrations of CLZ on oocyte maturation are similar to 
those found in healthy humans who were reported in clinical trials. 
• Prolonged arrest of oocyte maturation at the germinal vesicle stage is 
harmful and the arrested oocytes are undergoing degeneration.  
• Sustained high level and/or accumulation of cAMP in the arrested oocytes 
may explain the noted oocyte degeneration. 
• Degenerated immature oocytes have 2 distinctive patterns; vacuolated 
and fragmented. 
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CHAPTER III 
CILOSTAZOL INHIBITS OOCYTE MEIOTIC  
MATURATION IN SUPEROVULATED MICE  
 
Overview 
Previously, we evaluated the inhibitory effects of CLZ on oocyte maturation. We 
found CLZ is able to block oocyte maturation in vitro. Here, we investigated the 
influence of time of administration of CLZ on oocyte meiotic maturation in vivo 
and defined protocols for the collection of ovulated oocytes of different meiotic 
stages. Mice were superovulated and gavaged with 0, 7.5, or 15mg CLZ, once 
or twice, at various times around human chorionic gonadotropin (hCG) injection. 
Ovulated oocytes were collected at different time points and analyzed for 
maturation and cAMP levels. CLZ resulted in the ovulation of metaphase I 
oocytes after a single dose of CLZ as early as 9h pre-hCG. This inhibitory effect 
was greater when CLZ administration was closer to the hCG injection time with 
an increase in germinal vesicle oocyte yield, especially with two doses of CLZ. 
The inhibitory effect of CLZ disappeared when administered 4h post-hCG. 
Ovulated GV oocytes had low cAMP levels in comparison to ovarian GV 
oocytes, which may be attributed to gap junction interruption and/or CLZ plasma 
concentration reduction. It is concluded that CLZ inhibits oocyte meiosis with a 
wide range of times of administration, which accounts for its contraceptive 
properties. Acquisition of oocyte meiotic competence in the oviduct upon late 
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collection indicates CLZ reversibility and can be utilized to synchronize oocyte 
meiotic and cytoplasmic maturation in superovulation. Finally, protocols for 
ovulating meiotically immature oocytes are presented that can substitute for 
conventional ovarian immature oocyte recovery. 
 
Introduction 
The capability of the ovarian oocyte to undergo spontaneous oocyte meiotic 
maturation in vitro was first observed by Pincus and Enzmann in 1935. An 
inhibitory role for cAMP on spontaneous maturation was suggested in 1974 by 
Cho et al. after observing in vitro inhibition of oocyte meiotic maturation caused 
by dibutyryl cAMP and theophylline. In 1983, Vivarelli et al. observed the inverse 
relationship between cAMP concentration and oocyte meiotic maturation. Cyclic-
AMP synthesis by the somatic cells surrounding oocytes was confirmed the 
same year, further supporting the inhibitory role of cAMP on oocyte meiotic 
maturation. Moreover in 1983, Schultz et al. demonstrated oocyte meiotic 
maturation inhibition by the three cAMP augmenting loops: adenylate cyclase 
activation, PDE inhibition, and cAMP analogues. They also presented the first 
evidence of cAMP regulating oocyte meiotic maturation in vivo. One year later, 
oocyte PDE was found to play a detrimental role in meiotic competence through 
controlling oocyte cAMP hydrolysis (Bornslaeger et al. 1984). In 1985, other 
cAMP related molecules such as adenosine and hypoxanthine were detected in 
oocyte follicular fluid (Eppig et al. 1985). In later decades, countless studies 
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were conducted and PDE-Is were found to prevent bovine (Thomas and 
Armstrong 2002; Thomas et al. 2004), porcine (Grupen et al, 2006; Miyano et al. 
1995), rodent (Nogueira et al. 2003a; Tsafriri et al. 1996; Wiersma et al. 1998), 
monkey (Curnow et al. 2011; Jensen et al. 2002), and human (Nogueira et al. 
2003b; Shu et al. 2008; Vanhoutte et al. 2007) oocyte meiotic maturation in vitro. 
Those PDE-Is were also able to arrest oocyte meiotic maturation in vivo in 
rodents (Wiersma et al. 1998) and monkeys (Jeffrey et al. 2010; Jensen et al. 
2005 and 2008) and to block pregnancy in rodents (Wiersma et al. 1998) and 
monkeys (Jeffrey et al. 2010).  
Phosphodiesterase 3A is the predominant PDE3 isoform in oocytes. The 
gain of meiotic competence was observed after peak PDE3A activity, indicating 
a pivotal prerequisite role for increasing PDE3A activity prior to meiotic 
competence. On the other hand, oocytes deficient in PDE3A were found to have 
a sustained cAMP level and failed to undergo in vitro maturation (Masciarelli et 
al. 2004; Richard et al. 2001; Sasseville et al. 2006). In contrast to intra-oocyte 
cAMP, the surrounding somatic cell cAMP was reported to play the opposite role 
in meiotic maturation. Increasing follicular cell cAMP is achieved via PDE4 
inhibition and was found to induce in vitro meiotic maturation of follicular 
oocytes. Oocytes enclosed within follicles and incubated with rolipram (PDE4 
inhibitor) underwent GVBD; however, spontaneous meiotic maturation of 
denuded oocytes was not arrested by rolipram but was arrested by PDE3-I. In 
addition to the opposite roles of somatic and germinal cAMP, PDE3 and PDE4 
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were found to be compartmentally localized in oocytes and granulosa cells, 
respectively (Tsafriri et al. 1996). Interestingly, PDE4 is believed to associate 
with other reproductive endocrinological events. In this regard, mice which 
lacked PDE4 showed a defect in ovulation and impaired fertility, whereas 
administration of a PDE4 inhibitor in FSH-primed rats resulted in ovulation of 
normal oocytes, indicating that PDE4 inhibitors can substitute for hCG in 
superovulation protocols (Conti 2011; Mayes and Sirard 2002; McKenna et al. 
2005;  Park et al. 2003). 
The surge of LH, in addition to ovulation induction, triggers oocyte meiotic 
resumption. While many studies suggest different molecular mechanisms by 
which LH induces meiotic maturation of the follicular oocytes, the gap junction 
communication (GJC) disruption theory is the most common understanding. 
Interruption of communication between the somatic and germ cells has been 
confirmed as a prerequisite for meiotic maturation. Luteinizing hormone was 
observed to increase follicular cell production of cAMP and to block the 
numerous gap junctions in mural granulosa and cumulus cells via mitogen-
activated protein kinase activation (Hashimoto et al. 1988; Isobe et al. 1998; 
Norris et al. 2008). Importantly, the administration of a gap junctional blocker has 
been shown to arrest maturation of follicular oocytes in vitro and in vivo (Sela-
Abramovich et al. 2006 and 2008). Active gap junctions were found to provide 
oocytes with meiotic inhibitory substances such as cGMP. A dramatic loss of 
junction net area and interactions are indeed correlated with meiotic competence 
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(Larsen et al. 1986; Norris et al. 2009). High intraoocyte cAMP concentrations 
build the free catalytic subunit of protein kinase A (PKA) leading to deactivation 
of the M phase promoting factor and arrest of meiotic maturation (Han and Conti 
2006; Oh et al. 2010). 
In this study, we studied CLZ and tested its ability to reduce oocyte 
maturation in vivo using mice. We also defined the range of times of 
administration at which CLZ can start and lose its inhibitory effects in 
superovulated mice. We further examined the capability of obtaining ovulated 
oocytes that are meiotically immature; GV and/or MI, depending upon the dose, 
time, and frequency of CLZ administration. We then monitored the capability of 
the ovulated immature oocytes to initiate and to continue the meiotic maturation 
process in the oviduct to determine if we can have an additional method to 
obtain immature oocytes and to aid synchronization of oocyte meiotic maturation 
in vivo during superovulation.   
 
Materials and methods 
Animals 
Swiss Webster mice (8-10 weeks old) were purchased from Harlan Laboratories 
(Houston, TX). Mice were housed in the Texas A&M University Laboratory 
Animal Facility in groups of 5-8 mice per cage under controlled temperature 
(23°C) and light/dark (14/10 h) cycle. Food and water were provided ad libitum. 
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All experiments and procedures were approved by the Texas A&M University 
Institutional Animal Care and Use Committee.  
 
Chemicals and reagents 
Pregnant mare serum gonadotropin (Folligon®) and hCG (Chorulon®) were 
purchased from Intervet Inc (Summit, NJ). Leibovitz's L-15 medium was 
purchased from Invitrogen (Grand Island, NY). Human tissue fallopian (HTF) 
medium with HEPES for murine IVF was obtained from Zenith Biotech (Guilford, 
CT). Bovine hyaluronidase and DMSO were purchased from Sigma (St. Louis, 
MO). CLZ was purchased from LKT Laboratories (St. Paul, MN). 
 
Cilostazol dose determination 
Cilostazol volume of distribution (Vd), as determined in humans, was used to 
determine the dosage of CLZ for the mouse. In humans, a non-compartmental 
model showed an apparent Vd of 2.76L/kg suggesting an extensive tissue 
distribution (Bramer et al. 1999), whereas a two-compartmental model 
suggested volumes of central and peripheral compartments of 20.5 and 73.1L, 
respectively (Yoo et al. 2010). The later model had a better fit than the one-
compartment model when Vd was considered for mice, as shown by our 
extrapolated doses. Previously, we determined the in vitro inhibitory CLZ 
concentrations on denuded oocyte meiotic maturation in mice (Chapter II). The 
 38 
 
inhibitory CLZ concentration was based on CLZ plasma concentrations of 
people who are taking cilostazol. Starting from the highest in vitro inhibitory 
concentrations (relevant to the reported highest human CLZ plasma 
concentration) as the desired initial mouse plasma concentration and the 
reported human central Vd, the 7.5 and 15mg doses, used in these experiments, 
were determined and were found to be effective in arresting oocyte meiotic 
maturation in vivo. 
 
Experimental design 
These experiments were designed to test the following hypotheses: 1) CLZ 
inhibits oocyte meiotic maturation in superovulated mice; 2) The effect of CLZ on 
oocyte meiotic maturation is reversible; 3) The doses and times of administration 
of CLZ with respect to hCG injection influence the meiotic maturation stage of 
the ovulated oocytes; 4) Immature oocytes are able to resume meiotic 
maturation in the ovary and/or oviduct at various times after CLZ administration. 
Fig. 3.1 shows the design of the experiments that were conducted to test these 
hypotheses. 
All animals were injected intraperitoneally, at 6:00pm, with 7.5IU PMSG 
and after 47h with 7.5IU hCG. CLZ doses of 7.5 or 15mg were dissolved in 0.1 
or 0.15ml DMSO, respectively, and administered fresh to mice via gastric 
gavage at 9, 7, or 4h pre-hCG, at the same time as hCG, or 2 or 4h post-hCG. 
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Some animals were treated twice with 7.5mg CLZ at 4h pre-hCG and 2h post-
hCG and others at the same time as hCG and 6h post-hCG. 
 
 
 
 
 
Figure 3.1. The experimental design of oocyte collection at different times post-hCG from mice 
treated with CLZ of different doses and at different times of administration. 
 
 
Oocyte retrieval 
Anesthetized animals were sacrificed by cervical dislocation and oocytes were 
collected 13-13.5h (early collection) or 14.5-15.5h (late collection) post-hCG 
injection. Ovaries and oviducts were excised and placed into 2ml of L-15 
medium supplemented with 10% BSA and 4.2µM CLZ to prevent spontaneous 
oocyte meiotic maturation (Chapter II). The visibly distended region of the 
oviductal ampulla was punctured, and the ovulated CEO complexes were 
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collected and transferred to 1ml of 0.006% bovine hyaluronidase (dissolved in L-
15 medium plus 10% BSA and of 4.2µM CLZ) for less than 1.5 minutes with 
occasional pipetting. Denuded oocytes were transferred again to 1ml medium 
similar to the initial medium and scored for maturational status as GV, MI, or MII 
(Wassarman et al. 1976) using a Nikon SMZ1500 stereomicroscope and 
Olympus IX71 inverted microscope. Control animals received the designated 
DMSO volumes at the same time as CLZ, and oocytes were collected at the 
same time as the treated animals to evaluate their oocyte meiotic maturation. 
The entire technique was conducted on a warm stage set at 38°C. 
 
Determination of GVBD timing in superovulated mice 
Non-treated female mice were superovulated as described in the previous 
section and oocytes were collected at 3, 6, or 9h post-hCG. The ovaries were 
excised in 1ml HTF medium supplemented with 10% BSA and 4.2µM CLZ. 
Oocytes were isolated as described previously (Wiersma et al. 1998) and 
assessed for their maturational stage. 
 
Cyclic AMP assay 
Cyclic AMP concentrations were measured in ovulated GV oocytes retrieved 
from animals treated with 7.5mg CLZ administered at the same time as hCG and 
6h post-hCG, ovulated MI oocytes retrieved from animals treated with 7.5mg 
CLZ at 4h pre-hCG, and ovulated MII oocytes retrieved from non-treated mice 
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(negative control). Ovarian denuded GV oocytes from PMSG-primed mice were 
collected after 47h and used as positive controls. Pools of 40-65 oocytes per 
sample were used to assess cAMP contents. However, for the ovulated oocytes, 
the levels of cAMP were below the limit of the assay. Therefore, in some 
subsequent experiments, pools of 140-150 ovulated oocytes were analyzed (4-6 
replicates). Briefly, ovarian GV or ovulated GV, MI, or MII oocytes were collected 
in HTF medium with 4.2µM CLZ supplemented with 10% BSA. Oocytes were 
denuded from cumulus cells, washed, and placed in 125µl of 0.1M HCl for 10 
minutes at room temperature with occasional vortexing. The samples were 
centrifuged for 10 minutes at 800g. Supernatants were kept at -20°C until 
analyses by an ELISA cAMP kit from Biomol Research Laboratories 
(Farmingdale, NY, USA) using an acetylating protocol as described in the 
manufacturer’s instructions. 
 
Statistics 
A Chi square test was used to evaluate the differences between CLZ-treated 
and control animals and between the 7.5 and 15mg CLZ-treated animals for 
similar oocyte maturation stage of the same treatment time-point. The Kruskal-
Wallis test followed by the Mann-Whitney U post hoc test was used to compare 
differences within each treatment time point and to compare differences of each 
oocyte maturational stage among different treatment time groups for each tested 
dose. The same analysis was used to test the differences in proportions of 
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GVBD oocytes in superovulated non-treated mice. Data from early and late 
oocyte collections of each cell-type were subjected to arcsine square-root 
transformation to normalize data before Student T-test was used. The Student 
T-test analysis was also used to analyze the difference between cAMP 
concentrations of ovulated and ovarian GV oocytes. The threshold for significant 
difference was set at P<0.05, and SPSS® 14.0 software (SPSS Inc., Chicago, 
IL) was used to carry out the statistical analyses. 
 
Results 
Single CLZ dose inhibited oocyte meiotic maturation 
Early collection of oocytes from animals treated orally with single CLZ doses of 
7.5 or 15mg, at the indicated times except for the 4h post-hCG time point, 
inhibited oocyte meiotic maturation at MI or at GV and MI, significantly 
(p<0.0001), when compared to relevant oocyte types from control animals in 
which more than 97% of ovulated oocytes were at the MII stage (Fig. 3.2 and 
3.3). The overall trend of ovulated oocytes in animals treated with a single CLZ 
dose of 7.5mg showed a higher distribution for MI oocyte than other cell types  
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Figure 3.2. Cilostazol (7.5mg) effects on oocyte meiotic maturation in superovulated mice. 
Animals were superovulated and treated with CLZ (7.5mg/0.1ml DMSO) at the indicated times 
and ovulated oocytes were scored for meiotic status 13.00-13.5h post-hCG (A). Animals were 
superovulated and treated with 0.1ml DMSO (vehicle control) at the corresponding timings and 
ovulated oocytes were scored for meiotic status 13.00-13.5h post-hCG (B). Number at the top of 
each administration time is the total number of scored oocytes. Data are presented as oocyte 
percent from the total number of oocytes. Values with no common superscript within each 
treatment time are significantly different (p<0.05) using the Mann-Whitney test.  
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Figure 3.3. Cilostazol (15mg) effects on oocyte meiotic maturation in superovulated mice. 
Animals were superovulated and treated with CLZ (15mg/0.15ml DMSO) at the indicated times 
and ovulated oocytes were scored for meiotic status 13.00-13.5h post-hCG (A). Animals were 
superovulated and treated with 0.15ml DMSO (vehicle control) at the corresponding timings and 
ovulated oocytes were scored for meiotic status 13.00-13.5h post-hCG (B). Number at the top of 
each administration time is the total number of oocyte scored. Data are presented as oocyte 
percent from the total number of oocytes. Values with no common superscript within each 
treatment time are significantly different (p<0.05) using the Mann-Whitney test.  
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(Fig. 3.2A) at all tested time points except for two times of administration; 9h pre-
hCG and same as hCG. The 9h pre-hCG administration allowed mice to ovulate 
more MII than MI oocytes (61.8% vs. 38.12%, P=0.1). Administration of CLZ at 
the time of hCG showed that GV oocytes were the predominant cell-type over 
the MI and MII oocytes (62.73% vs. 31.17% and 6%, P=0.1 and P<0.0001, 
respectively). The predominant GV oocyte ovulation with single CLZ dose 
administered at the time of hCG injection could be attributed to sufficient 
inhibitory CLZ blood concentration to block the early events of oocyte GVBD and 
thus delay the resumption of maturation. The characteristic MI oocyte ovulation 
in the single dose of 7.5mg  CLZ treated animals was more marked in the 
groups treated at 7 and 4h pre-hCG  than other times (P<0.01, Fig. 3.2A). 
Metaphase I oocyte ovulation prevalence continued with the 15mg CLZ dose 
(Fig. 3.3A) and was reduced only when CLZ was administered at the time of 
hCG due to increased GV oocyte ovulation over MI and MII oocytes (71.3% vs. 
24.34% and 4.3%, respectively, P<0.04 for both). This could be due to the 
sufficient inhibitory concentration of CLZ in the circulation mentioned previously. 
The ovulation of MI oocytes also decreased at the 4h post-hCG time point due to 
increased ovulation of MII over MI oocytes (87.37% vs. 12.62%, P=0.003, Fig. 
3.3A). Neither MI nor MII oocyte yield between CLZ and DMSO treatments at 4h 
post-hCG differ significantly (P>0.05), indicating a lack of CLZ arresting 
capability at this time point (Fig. 3.3). This administration time point (4h post-
hCG) represents a cutoff at which PDE3-I is ineffective in impeding oocyte 
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meiotic maturation as the LH like activity of the hCG hormone is assumed to 
trigger meiosis events shortly after its administration.  
Although administration of 7.5mg CLZ, 9h pre-hCG, resulted in more MII 
than MI ovulated oocytes (61.8% vs. 38.12%, P=0.1, Fig. 3.2A), the 
administration of 15mg at this time point reversed the effect and resulted in mice 
ovulating more MI oocytes than MII (65% vs. 33.9%, respectively, P=0.006, Fig. 
3.3A), which is an evidence of a dose response effect. Also, the 15mg 
administration at this time-point resulted in more MI and fewer MII oocytes than 
did 7.5mg (P=0.0001, for both cell types). Animals treated with 7.5 or 15mg CLZ 
at 7h pre-hCG, ovulated mainly MI oocytes (>95%) with less than 4% MII 
oocytes (P<0.004), whereas animals treated 4h pre-hCG with 7.5 or 15mg CLZ 
ovulated only MI (>75%) and GV (<24%) oocytes with a significant difference 
(P<0.003) between the only two ovulated oocyte types. The 4h pre-hCG time 
treatment of 7.5 or 15mg CLZ resulted in a complete immature oocyte ovulation 
at combined GV and MI levels with no MII ovulation (P<0.05) in comparison to 
other times of administration. Moreover, comparing 7.5 to 15mg CLZ at 4h pre-
hCG resulted in a significant increase of GV oocytes (10.8% vs. 24.1%, 
P=0.005, respectively) and decrease of MI oocyte ovulation (89.1% vs. 75.8%, 
P=0.005, respectively), demonstrating another dose response effect. Both doses 
of 7.5 or 15mg administered at 7h or to a lesser extent at 4h pre-hCG were 
sufficient to synchronize the ovarian oocyte GVBD and to uniformly ovulate a 
majority of MI oocytes (Fig. 3.2A and 3.3A). The ovulated oocytes at GV stage 
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started to increase notably (P<0.005) first in the single CLZ treatments (7.5 or 
15mg) at the 4h pre-hCG time-point. This trend continued with CLZ 
administration at hCG or 2h post-hCG timing, with the highest GV oocyte yield at 
hCG injection. The GV oocyte rates from the GV ovulating protocols were not 
significantly different (Fig. 3.2A and 3.3A). The mixed ovulation of GV, MI, and 
MII oocytes started when CLZ of 7.5 or 15mg was administered 2h post-hCG 
with marked MI oocyte ovulation over MII oocytes (P<0.04). Figure 3.4 shows 
oocytes of different meiotic developmental capacity at early collection of oocytes 
from female mice treated with different CLZ protocols. 
 
Multiple CLZ doses inhibited oocyte maturation at GV stage 
Administration of 7.5mg CLZ, BID; 4h pre-hCG and 2h post-hCG or at the same 
time as hCG and 6h post-hCG, resulted in mice ovulating GV oocytes in 
comparison to lack of GV oocytes in their relevant control animals (P<0.0001, for 
both protocols, Fig. 3.5A). The ovulated GV oocytes in both protocols were 
greater than their corresponding MI oocytes (89.7% and 96% vs. 10.2% and 4%, 
respectively, P<0.003). The ovulated MI oocytes in those mice were significantly 
greater than the ovulated MII oocytes (P<0.03, for both protocols). The two 
protocols did not significantly differ in GV oocyte arresting capability at early 
collections (P=0.2) but resulted in the ovulation of significantly more GV oocytes 
than the single CLZ dose regimens (P<0.0001). Figures 3.5B and C show the 
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effect of multiple administrations of CLZ on oocyte meiotic maturation in 
superovulated mice.   
 
 
 
 
 
Figure 3.4. Ovulated oocytes with different meiotic developmental stage in early collected 
oocytes. Note the uniform MI oocyte ovulation in animals treated with 7.5 or 15mg CLZ at 4h 
pre-hCG (A and B, respectively). Note the ovulation of oocytes of mixed maturational stages of 
mainly GV and MI/MII oocytes from animals treated with 15 or 7.5mg CLZ at the same time as 
hCG (C and D, respectively). Note the ovulated oocytes of different maturational stages of 
mainly MII and MI oocytes and few GV oocytes form a female mouse treated with 15 or 7.5mg at 
2h post-hCG (E and F, respectively). 
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Figure 3.5. Multiple CLZ administrations in mice allow for GV oocyte ovulation upon early 
retrieval. Administration of 7.5mg CLZ in multiple doses at 4h pre-hCG and 2h post-hCG or 
same time as hCG and 6h post- hCG allowed for ovulation of GV oocytes. (A). Animals treated 
with 7.5mg CLZ at the same time as hCG and 6h post- hCG allowed a uniform GV oocyte 
ovulation upon retrieval (B). The same observation was noted in animals treated with 7.5 mg at 
4h pre-hCG and 2h post-hCG (C). Delaying GV oocyte collection in animal treated with 7.5mg 
CLZ at 4h pre-hCG and 2h post-hCG resulted in MI oocyte collection (D). Data are presented as 
oocyte percent from the total number of oocytes. Values with no common superscript within each 
treatment time are significantly different (p<0.05) using the Mann-Whitney test. 
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Meiotic maturation initiation and continuation in the oviduct 
In some experiments, oocyte collections from CLZ-treated animals were delayed 
until 14.5-15.5h post-hCG (late collection) to determine if ovulated immature 
oocytes at a specific meiotic maturation stage could initiate or finish meiotic 
maturation in this superovulated mouse model. The late collection of oocytes 
from animals treated with 7.5mg CLZ, 9h pre-hCG, showed a mean decrease in 
MI and an increase in MII oocytes when compared to those of early  
oocyte collections (1.8% vs. 38.5% and 98.1% vs. 61.3%, respectively, 
P<0.0001, for both, Fig. 3.6A). A similar observation was noted with the same 
doses but at 7h pre-hCG administration (P<0.0001, Fig. 3.6B), indicating the 
capability of ovulated immature oocytes at MI in animals treated with 7.5mg 
CLZ, 7 or 9h pre-hCG, to finish the process of meiotic maturation in the oviduct 
at this relatively short period of delayed collection. The scoring of ovulated GV 
and MI oocytes from late collection in animals treated with 7.5 or 15mg CLZ, 4h 
pre-hCG, revealed a significant increase in MI oocytes (P<0.01, for both doses) 
associated with a GV oocyte decrease (P<0.01 for 15mg treated mice) in 
comparison to those in early collection (Fig. 3.6C and D). These late collections 
displayed the ability of ovulated GV oocytes to start the process of GVBD in the 
oviduct and the inability of the ovulated MI oocytes to reach the MII stage within 
this time window of delayed collection. The initiation of GVBD and MI 
progression to the MII stage were observed together in late collections of 
oocytes from animals treated with 7.5mg CLZ at the same time as hCG (Fig.  
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Figure 3.6.  Late collection of ovulated oocytes from animals treated with CLZ allowed for some 
oocytes to resume and/or finish meiotic maturation. The late collection of oocytes from mice 
treated with 7.5mg CLZ dose, 9 h pre-hCG, led ovulated MI oocytes to finish maturation and 
reach the MII stage (A). The same observation was noted in 7.5mg CLZ treated animals, 7h pre-
hCG (B). In animals treated with a single 15mg CLZ dose, 4 h pre-hCG, ovulated GV oocytes 
initiated meiosis and reached the MI stage in the oviduct at late collection (C). The same 
observation was noted in animals treated with single 7.5mg CLZ dose, 4h pre-hCG (D). Both 
ovulated GV and MI oocytes continued meiotic maturation to MI or MII, respectively in animals 
treated with 7.5mg CLZ dose at the same time as hCG (E). Data are presented as mean ± SEM 
percent. Differences were analyzed between the same oocyte maturation stage of early and late 
collections using Student T independent test. *<0.05, **<0.01, ***<0.001, and ****<0.0001. 
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3.6E). The ovulated GV oocytes underwent GVBD in late collected oocytes 
(66.75% vs. 18%, P<0.0001) which was accompanied by an MI oocyte increase 
(27.6% vs. 67.7%, P<0.001). Conversely, some of the ovulated MI oocytes were 
able to finish meiotic maturation at late collection and reached the MII stage 
(5.4% vs.13.8%, P<0.05). This phenomenon of concurrent events of GVBD and 
first polar body emission may be explained by the fact that both hCG and CLZ 
have similar onsets of action on follicles. As a result, some oocytes showed 
responses to hCG before attaining CLZ inhibitory plasma concentrations while 
others were blocked by CLZ. Figure 3.7 shows photographs of oocyte meiotic 
maturation in late collections from animals treated with different CLZ protocols. 
 
 
 
 
 
 
Figure 3.7. Delayed collection of ovulated oocytes in animals treated with CLZ allowed some of 
the immature oocytes to resume/finish meiotic maturation in the oviduct. Delayed oocyte 
collections from animals treated with 7.5mg CLZ, 9h pre-hCG, allowed the ovulated MI oocytes 
to reach MII stage (A). Animals treated with 15mg at 4h pre-hCG allowed a majority of GV 
oocytes to undergo GVBD when oocyte collection was delayed (B). Animals treated with 7.5mg 
CLZ at 4h pre-hCG allowed for the ovulated GV oocytes to undergo GVBD and for the ovulated 
MI oocytes to show signs of first polar body emission as indicated by arrows (C). 
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The ovulated GV oocytes (89.7%) in animals treated with 7.5mg CLZ, 4h 
pre-hCG and 2h post-hCG, were dramatically decreased at delayed collection to 
32.2% (P<0.0001) accompanied with increased average numbers of collected 
MI oocytes (8% vs. 67.3%, P<0.01, Fig. 3.8A). The same case was recorded at 
late collection in animals treated with 7.5mg CLZ at the same time as hCG and 
6h post-hCG but with a great variation (Fig. 3.8B). Four out of eight treated 
animals showed more than 85% GV oocytes at late collection while the other 4 
showed mainly MI oocytes (standard deviations of 14.84 and 11.53 for GV and 
MI oocytes at late collection, respectively). Figure 3D show a photograph of 
uniform collection of MI oocytes at delayed collection. 
 
 
 
 
 
Figure 3.8: Delayed collection of ovulated oocytes in animals treated with multiple doses of CLZ 
allowed GV oocytes to resume meiotic maturation in the oviducts. Ovulated oocytes at early and 
late collections from animals treated with 7.5mg CLZ at 4h pre-hCG and 2h post-hCG (A) or at 
the same time as hCG and 6h post-hCG(B). Data are presented as mean ± SEM. Differences 
are analyzed between the same oocyte maturation stage of early and late collections.  
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GVBD monitoring in superovulated non-treated animals 
In this experiment, we defined the time required for GVBD to occur in 
superovulated, non-CLZ-treated, the Swiss Webster mouse strain and found that 
98% of the oocytes were at the GV stage surrounded by compact cumulus cells 
vs. 2% at the MI stage (P<0.0001) when oocytes were collected 3h post-hCG 
(Fig. 3.9A). This time-point showed the earliest time of oocyte GVBD to occur in 
this superovulated strain. Collection of oocytes at 6h post-hCG continued to 
show prevalence of GV oocytes over MI oocytes and MI oocytes over MII 
oocytes (69.3% vs. 28.1% vs. 1.98%, P=0.001 and P<0.0001, respectively). 
Most importantly, this time point-showed the first evidence of the earliest time 
that complete oocyte meiotic maturation can occur in superovulated mice. This 
phenomenon points to possible aging and viability reduction in oocytes that 
mature in a considerable time period (7-8h) before ovulation and also points to 
the importance of oocyte synchronization in superovulation protocols. Collection 
of oocytes at 6h post-hCG showed that more than 80% of the recovered oocytes 
were denuded or partially denuded (P<0.0001), while more than 90% of the EOs 
displayed cumulus expansions (P<0.0001). The recovery of denuded oocytes 
may be due to the loose and non-tenacious expanded cumulus cells that were 
lost during mechanical manipulation. Finally, aspirating oocytes after 9h post-
hCG showed similar proportions of the three oocyte types with no significant 
differences. All those oocytes were surrounded with tenacious expanded  
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Figure 3.9. Monitoring oocyte meiotic maturation acquisition at different time points in 
superovulated mice. Animals were injected with ECG and after 47h with hCG. Oocytes were 
scored at 3, 6, or 9h post-hCG to define the time course of meiotic maturation acquisition after 
hCG (A). Ovarian oocytes surrounded by compact cumulus cells collected at 3h post-hCG (B). 
Ovarian oocytes collected at 9h post-hCG showing tenacious expanded cumulus cells (C). Note 
the oocyte complex aggregates upon ovulation (D). Data are presented as oocyte percent from 
the total number of collected oocytes. Number at the top of each collection time is the total 
number of oocytes collected. Values with no common superscript within each collection time are 
significantly different (p<0.05) using the Mann-Whitney test.  
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cumulus cells which might explain CEO complex aggregations and adhesions 
upon ovulation (Fig. 3.9B-D). 
 
Cyclic cAMP level in ovulated immature oocytes 
Cyclic AMP concentrations in ovulated GV oocytes were significantly lower than 
ovarian GV oocytes (P<0.0001). When pools of 40-65 oocytes per sample were 
evaluated, the content of cAMP from ovulated GV, MI, and MII oocytes were 
below the limit of the assay. Increasing the number of oocytes in the pools to 
140-150 oocytes, resulted in the detection of cAMP in ovulated GV oocytes; 
however, by comparison, a markedly greater level of cAMP was detected from 
the smaller pool of 40-65 ovarian GV oocytes (Fig. 3.10). 
 
 
 
 
Figure 3.10. Cyclic AMP concentrations of ovulated and ovarian GV oocytes. Number at the top 
of each group is the total number of oocyte assayed. **** <0.0001 using the Student T test. Data 
are presented as mean±SD. 
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Discussion  
We have previously shown for the first time that CLZ was able to block in vitro 
and in vivo oocyte meiotic maturation and pregnancy in mice (Taiyeb-Ridha et 
al. 2011a, b, and c) in concentrations and doses extrapolated from those in 
people who are taking CLZ. Here, we defined the timing of oocyte GVBD in 
superovulated Swiss Webster mice at 3 different time-points after hCG hormone 
injection and concluded that the process of GVBD was continuous from 3-9h 
post-hCG administration. We further controlled this breakdown via CLZ oral 
administration and allowed for GV, MI, MII, or mixed maturational stage oocytes 
to be ovulated based on the CLZ administration time, dose, and/or oocyte 
retrieval time. These protocols for retrieval of ovulated immature oocytes can be 
utilized as an additional research tool to the conventional method of ovarian 
collection of GV oocytes and subsequent in vitro maturation to obtain MI 
oocytes. The ovulated immature oocytes are characterized by high yield, easy 
retrieval, and uniform shape. On the other hand, these oocytes have lower levels 
of cAMP than the ovarian GV oocytes and are always surrounded by expanded 
cumulus cells and consequently lacked GJC.  
In this study, we have also shown that the CLZ blocking property on 
oocyte meiotic maturation is reversible. Cilostazol delayed the process of GVBD, 
and once the inhibitory CLZ concentrations were assumed to decline, the 
oocytes were able to launch meiotic maturation in ovaries and/or the oviducts. 
The ability of CLZ to allow animals to ovulate MI oocytes when CLZ was 
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administered almost one day before ovulation time (such as the 9h pre-hCG) 
does not mean CLZ has a one day duration of action nor can block oocyte 
maturation at MI level because delayed collections allowed the ovulated MI 
oocytes to gain full meiotic maturation in the oviducts. It means that CLZ 
administration at 9 or 7h pre-hCG, is able to maintain a sufficient inhibitory 
concentration for the first few hours post-hCG, and this can briefly block the 
early effects of LH on oocyte GVBD. This short delay in the ovarian oocyte 
GVBD allowed the GV oocytes to have barely enough time in the ovary and/or 
reasonably enough time in the oviduct, to finish meiotic maturation. This can 
explain the ovulation of mixed MI and MII oocytes with the lack of GV oocytes 
collected early from animals treated with CLZ at 7 or 9h pre-hCG.  
A similar hypothesis can be suggested for the ovulated GV and MI 
oocytes in animals treated once or twice with CLZ close to the time of hCG 
administration. At these times (such as the 4h pre-hCG and at the same time as 
hCG), we suggest that inhibitory concentrations of CLZ in blood may be 
maintained for longer periods after hCG as opposed to the earlier 
administrations of CLZ at 7 or 9h pre-hCG. These longer inhibitory CLZ periods, 
post-hCG, delayed the events that precede GVBD such that ovarian GV oocytes 
did not have enough time to fully resume meiotic maturation before ovulation; 
thus, leading to ovulation of GV and MI oocytes. Although these ovulated GV 
oocytes were able to undergo GVBD on delayed collections, the MI oocytes 
failed to emit the first polar body in the oviducts because this time window of 
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delayed collections was insufficient for this process to occur in those fresh MI 
oocytes (GVBD is thought to occur shortly before or after the ovulation). This 
demonstrates that the longer the arrest of ovarian oocytes at the GV stage, the 
more time required for the oviductal GV and MI oocytes to initiate the transition 
to the MI and MII stages, respectively. 
Although the numbers of ovarian oocytes that underwent GVBD were low 
when oocytes were scored at 3 and 6h post-hCG injection, animals treated with 
CLZ 2 or 4h post-hCG injection ovulated MII oocytes. It is suggested that once 
the hCG effects on oocytes are triggered, the meiotic maturation is ultimately 
achieved. The hCG hormone has been shown to induce expression of epidermal 
growth factors (EGF) in preovulatory follicles (1h after being injected and 
reaching a peak after 3h). Those EGF family members are responsible for 
bringing the same morphological and functional events triggered by LH on 
follicles, such as cumulus cell expansion, GVBD (even when the spontaneous 
CEO meiotic resumption was arrested with PDE-I), and ovulation (Ashkenazi et 
al. 2005; Park et al. 2004). Follicles incubated with LH for 0.5-2h showed 
reduction of gap junction permeability; a phenomenon that precedes GVBD 
(Norris et al. 2008; Sela-Abramovich et al. 2008). Moreover, LH stimulation of 
cultured preovulatory follicles resulted in a decrease in the content of cGMP with 
nadir at 1.5h; cGMP is a nucleotide that maintains oocytes meiotically immature. 
The same trend of cGMP content reduction was observed in oocytes isolated 2h 
post-hCG in superovulated mice (Vaccari et al. 2009). These findings all point to 
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a rapid onset of action of LH that starts as early as 30min post-administration. 
Taken together, these results explain the inability of CLZ, when administered 
post-hCG, to prevent oocyte meiotic maturation.  It is concluded that some 
meiotic maturational molecular events were triggered and initiated shortly after 
hCG administration, and PDE-Is are unable to forestall the ultimate meiotic 
maturation once the meiotic maturation is launched molecularly. It is also 
concluded that the early events of hCG on oocytes precede the morphological 
GVBD feature by 3-6h in this mouse strain.  
It is important to direct attention to other factors, rather than the inhibitory 
CLZ concentration, that are influencing GVBD such as cumulus cell proliferation 
and expansion, GJC interruption, and cAMP concentrations of both somatic and 
germinal compartments. Those responses are direct consequences of hCG/LH 
hormonal effects on a selected cohort of follicles. Levels of GJC between the 
oocyte and somatic cells dramatically decreased upon mechanical isolation of 
the COC from the follicle. Although PDE-Is were shown to prolong GJC between 
the 2 compartments and to strongly block meiotic resumption (Dieci et al. 2011; 
Shu et al. 2008; Thomas et al. 2004), the LH and LH-like activity of hCG are 
believed to interrupt this communication prior to GVBD, to induce oocyte meiotic 
resumption, to decrease oocyte cAMP concentration, and to increase somatic 
cell cAMP production. This LH induced decrease in intraoocyte cAMP 
concentration, in vivo and in vitro, was found to be associated with interrupted 
follicular GJC and was not accompanied with elevated intraoocyte PDE3 activity, 
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suggesting follicular cAMP flow toward oocytes is important to arrest meiotic 
maturation (Hashimoto et al. 1988; Isobe et al. 1998; Norris et al. 2008; Sela-
Abramovich et al. 2006; Sherizly et al. 1988; Vaccari et al. 2009). In addition to 
cAMP, cGMP has been shown to flow through the numerous gab junctions into 
oocytes to inhibit cAMP hydrolysis. The LH was observed to lower cGMP levels 
in the somatic cells, and consequently in the oocytes in addition to blocking GJC 
leading to the resumption of meiosis (Norris et al. 2009; Sherizly et al. 1988; 
Vaccari et al. 2009). Finally, although somatic cAMP when transmitted to the 
oocytes can prevent oocyte meiotic maturation, its elevation at the somatic 
compartment was confirmed to induce follicular maturation (Tsafriri et al. 1996). 
To put these observations into context with ours, the ovulated GV oocytes in 
animals treated with CLZ are believed to show the same GJC interruption and its 
consequences (such as low cAMP and probably cGMP concentrations) upon 
hormonal influence. Those conditions favor oocyte GVBD. The GVBD 
stimulatory factors can be challenged with steady state CLZ plasma inhibitory 
concentrations (Taiyeb-Ridha et al. 2011c). Nevertheless, it is still expected for 
ovulated GV oocytes retrieved from animals with sufficient circulatory CLZ 
concentrations to have barely enough intraoocyte cAMP to prevent GVBD but 
not as high as that in ovarian GV oocytes. It is concluded that a lower level of 
intraoocyte cAMP can maintain a state of GV in ovulated oocytes in comparison 
to the higher levels in ovarian GV oocytes. The ovarian GV oocytes have higher 
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concentrations of cAMP because of the active communication with the somatic 
compartment that is lacked in ovulated oocytes. 
It is generally accepted that in vitro meiotic maturation of mouse oocytes 
derived from antral follicles takes approximately 18h, and the time duration 
required for in vitro GVBD is less than 4h. The spontaneous oocyte meiotic 
progression does not follow the pattern of in vivo oocyte meiotic maturation in 
superovulated females. Mouse strains differ in regard to time needed for oocytes 
to acquire meiotic maturation in vivo after the hCG/LH stimulus. Edwards and 
Gates (1959) reported that it required 4.5 to 8h for all oocytes to be in 
metaphase, while Calarco et al. (1972) found the GV oocyte type to be the 
predominant oocyte after 3h post-hCG injection using CF-I mice. Miao et al. 
(2004) showed a mean percent of 12.9% ±2.1 MII oocytes, recovered 8h post-
hCG in Kun-ming mice. In contrast to these in vivo meiotic acquisition durations 
after the hCG injection, others reported GVBD in vivo of less than 4h post-hCG 
using different strains (Hsieh et al. 2007; Kalous et al. 2012). Although a uniform 
distribution of the 3 cell types was recorded only at 9h post-hCG in this research, 
almost all ovulated oocytes were mature with complete lack of GV oocytes in 
superovulated, non-treated, mice. Nevertheless, it is predicted that only MI 
oocytes at 9h post-hCG will proceed to the MII stage and to ovulate in addition 
to the already available MII oocytes at this time point. Adding those MI oocytes 
to the MII oocytes at 9h post-hCG was in agreement with our average oocyte 
yield at ovulation. It is also suggested that oocytes which fail to undergo GVBD 
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9h post-hCG will undergo atresia. In our CLZ protocols, we were able to retain 
the oocyte GVBD in a specified time frame based on the CLZ protocol used 
instead of this continuous GVBD in oocytes along the period post-hCG injection. 
This aids synchronization of oocyte meiotic development and prevention of early 
polar body emission with consequent aging and compromised oocyte quality and 
fertility (Taiyeb-Ridha and Kraemer 2011b).  
From a contraceptive point of view, CLZ resulted in ovulation of a 
considerable number of MI oocytes in the superovulated mouse model when 
administered as far as 24h before ovulation. Moreover, CLZ blocked pregnancy 
in mated naturally cycling mice when administered daily (before and after 
mating), assuming ovulation of GV oocytes that failed to undergo meiotic 
maturation in the oviduct or gained meiotic maturation after long periods of 
arrest at the GV stage. Such oocytes would be aged, less viable, and 
incompetent (Taiyeb-Ridha et al. 2011c). Furthermore, the compound is 
relatively safe and is prescribed on a chronic basis in people with relatively 
advanced ages. The compound is indicated in people with IC disease, which is 
characterized by lower limb pain development upon walking due to selective 
femoral artery vasoconstriction. The unique secondary property of adenosine 
uptake inhibition, along with the primary PDE3-I mechanism, is believed to 
counterbalance the potential undesirable side effects of cAMP accumulation in 
platelets, vascular smooth muscle, and myocytes. This might explain the wide 
margin of safety of this compound over other PDE3-Is (Collins et al. 2005; 
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Kambayashi et al. 2003; Liu et al. 2001; Wang et al. 2001). These observations 
cumulatively suggest that CLZ is a potential and safe PDE3A-I contraceptive 
worthy of further studying and evaluation, even though the manufacturer of CLZ 
reported no observed impairment of fertility in rats (Otsuka America 
Pharmaceutical Inc. 2007; Sandoz Inc. 2004). 
Overall, CLZ`s capability of blocking oocyte meiotic maturation in vivo 
was notable when the compound was administered at any time from 9h pre-hCG 
to 2h post-hCG. The compound is not different from other more potent PDE3-Is 
in regard to inhibition of oocyte meiotic maturation and is recommended for 
additional mammalian contraceptive studies. Also, we have presented evidence 
of oviductal-oocyte meiotic maturation which can be utilized as an in vivo culture 
system to synchronize oocyte meiotic maturation in superovulation. Finally, 
these tested CLZ regimens allowed for retrieving oocytes in different meiotic 
maturation stages with more convenience that can be considered as alternatives 
to the conventional methods of collection of meiotically immature oocytes from 
ovaries.   
 
Summary and conclusion 
• CLZ treatment results in ovulation of immature oocytes in superovulated 
mice. 
• The evaluated CLZ doses in mice are similar to those indicated in 
humans for treatment of intermittent claudication.  
 65 
 
• CLZ inhibits oocyte meiosis with a wide range of times of administration, 
which accounts for its contraceptive properties.  
• Sustained high level and/or accumulation of cAMP in the arrested oocytes 
may explain the noted oocyte degeneration. 
• Oocyte meiotic maturation in superovulated mice can be controlled when 
a PDE3-I is administered at anytime between 9h pre-hCG and 4h post-
hCG; at least when the administered PDE3-I is CLZ. 
• Collection of ovulated GV, MI, MII and/or oocytes with mixed maturational 
states is achievable via administration of CLZ in the superovulated mouse 
and this can substitute for conventional ovarian immature oocyte 
recovery. 
• CLZ effect on meiosis is reversible, which can be utilized to synchronize 
oocyte meiotic and cytoplasmic maturation and progression in vivo and in 
vitro.  
• Ovulated GV oocytes have lower cAMP concentrations than ovarian GV 
oocytes and as a result the ovulated GV oocytes can resume meiosis in a 
short period of time.  
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CHAPTER IV 
CILOSTAZOL BLOCKS PREGNANCY IN NATURALLY CYCLING MICE 
 
Overview 
Incubation of immature oocytes with PDE3-Is was found to prevent oocytes from 
undergoing maturation. PDE3-Is were then evaluated in vivo and found to result 
in ovulation of immature oocytes. Concerns regarding inhibition of PDE3A that is 
expressed in heart and blood vessels discouraged further development of 
PDE3-Is as non-steroidal contraceptives. Cilostazol is a PDE3A-I that is 
approved for medical indications in humans and has an additional effect of 
adenosine uptake inhibition that is believed to counterbalance the undesirable 
outcomes resulting from PDE inhibition. The aim of this study was to determine 
the capability of CLZ to inhibit pregnancy using a naturally cycling mouse model. 
None of the mice treated with 7.5 or 15mg CLZ, BID, produced offspring 
whereas all of the control animals maintained pregnancy and delivered normal 
pups (P<0.0001). Remating of the females which had been previously treated 
with CLZ resulted in normal offspring and litter sizes that were similar to controls, 
indicating that the contraceptive effect is reversible at least after short term 
administration. It is concluded that CLZ is a potential non-steroidal contraceptive 
that merits further evaluation. 
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Introduction 
In 1958, Sutherland and Rall reported the discovery and characterization of the 
first second messenger; cAMP from biological tissues. They also noticed a 
hydrolytic activity that was influencing the discovered nucleotide (Kresge et al. 
2005; Rall and Sutherland 1958; Sutherland and Rall 1958). Not until four years 
later, Butcher and Sutherland (1962) purified and characterized the 1st PDE. 
During 70s and 80s, many other PDEs were discovered (Butcher and 
Sutherland 1962). PDEs were found to be expressed in almost all mammalian 
cells and organs. At the present time, PDEs are a large number of enzymes in at 
least 11 known distinct families and 21 different gene types (Bender and Beavo 
2006). Among those are PDE3 and PDE4 that are expressed in oocytes and 
granulosa cells and are capable of hydrolyzing cAMP and cGMP, respectively, 
to produce the corresponding oocyte states of meiotic maturation (Tsafriri et al. 
1996). Incubation of ovarian GV oocytes with PDE3-Is was found to efficiently 
arrest oocyte maturation at the GV stage. Although numerous experiments were 
conducted to examine this maturational inhibitory effect at the in vitro level, few 
experiments were conducted in vivo to study the possible utilization of PDE3-Is 
as potential therapeutic agents for birth control besides the current 
contraceptives. Wiersma et al. (1998) reported that PDE3-I suppresses oocyte 
meiotic maturation and consequent pregnancy without affecting ovulation and 
cyclicity in rodents. The evaluated PDE3-Is (cilostamide and Org 9935) 
decreased oocyte maturation without affecting the number of ovulated oocytes 
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(Wiersma et al. 1998).  Other investigators (Jensen et al. 2005 and 2008; Jeffery 
et al. 2010) conducted several experiments in primates using Org 9935. While 
the compound was able to arrest oocyte meiotic maturation in superovulated 
monkeys and in vitro, it failed to block pregnancy unless an Org 9935 plasma 
concentration of 300nM was achieved (Jensen et al. 2002, 2005, and 2008; 
Jeffery et al. 2010). No further experiments were conducted to extend the 
potential contraceptive effects of PDE3-I in vivo despite the promising in vitro 
findings. The primary restriction for extrapolating the in vitro experimentations to 
in vivo trials is thought to be due to the wide expression of the PDE3A in many 
cell and tissue types including myocytes, platelets, and vascular smooth muscle 
(Bender and Beavo 2006). Inhibition of this enzyme in the oocytes is assumed to 
influence the same enzyme in other organs and consequently to cause 
undesirable cardiovascular adverse effects.  
Cilostazol (Fig. 4.1) is one of the few PDE3A-I that has not been 
evaluated for such contraceptive purposes. The primary aim of this study was to 
evaluate CLZ, a quinolinone derivative that appears to be the safest of the 
PDE3-I compounds, as a potential non-steroidal contraceptive drug using a 
mouse model. 
 
 
 
 
  
 
Figure 4.1. Cilostazol chemical structure. 
that has the chemical name 
dihydro-2(1H)-quinolinone
 
 
 
Materials and methods
Animals and reagents 
Mature female and male Swiss Webster mice were purchased from Harlan 
Laboratories (Houston, TX) and 
animal facility.  Female and male mice of 5 and 6
kept in an air-conditioned room with
light/dark cycle. Food and water were provided 
research were fertility proven whereas the females were virgin. The male fertility 
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Cilostazol is a quinolinone derivative 
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl) butoxy]
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test was conducted by mating each male to 2 females and recording litter size in 
the 2 mated females. Males were considered proven fertile when the females 
were pregnant and gave live births with normal litter sizes. All mice were 
identified by cage numbers and ear notches; 2 weeks before the start of the 
experiment. The average weights of mice treated with 7.5 mg CLZ, 15 mg CLZ, 
0.15 ml DMSO, or 0.15 ml water were 25.95± 2.1 g, 25.3±3.2 g, 26.45±1.2 g, 
and 25.9±1.4 g, respectively.  The animals from different groups were not 
significantly different in weight. All the experiments and procedures were 
approved by the Texas A&M University Institutional Animal Care and Use 
Committee. Methylene blue and DMSO were purchased from Sigma (St. Louis, 
MO, USA) and CLZ was purchased from LKT Laboratories (St. Paul, MN, USA). 
 
Monitoring estrus  
Virgin female mice were checked for the stage and regularity of estrous cycles 
for 2 weeks by analyzing the vaginal cytology. Briefly, a small volume of normal 
saline was introduced into the vagina and aspirated back and forth for 2-3 times. 
The saline containing cells was placed on a slide, air dried, and stained with 1% 
methylene blue (of 70% methyl alcohol) for 5min. The slides were washed, 
dried, and analyzed under an Olympus IX71 inverted microscope. The metestrus 
phase of the estrous cycle was determined when leukocytes and nucleated and 
non-nucleated epithelial cells were detected in approximately equal proportions. 
Diestrus was determined when leukocytes were the predominant cell type, 
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whereas proestrus was identified by the presence of both nucleated and non-
nucleated epithelial cells, with a small number of cornified cells. Estrus was 
verified when large numbers of cornified epithelial cells were observed. Forty 
females with 3-5 day estrous cycles were selected for this experiment and 
treatments began when females exhibited the first proestrus after the 2 week 
period of estrous cycle monitoring.  
 
Cilostazol administration 
Females were randomly assigned to four treatment groups: 7.5mg or 15mg CLZ, 
DMSO (vehicle control), or 0.15ml water (negative control). Cilostazol doses of 
7.5 or 15mg were dissolved in 0.1 or 0.15ml DMSO, respectively. Cilostazol 
doses were prepared fresh just before administration. All treatments were 
administered orally by gastric gavage, twice a day, and each treatment group 
consisted of 10 females. Once the treatments were started, the vaginal smears 
were discontinued to exclude any possible interruption in mating. Females were 
placed with fertility proven non-treated males in a ratio of 1:1 three days after the 
initiation of treatments. Males were removed from the females when the seminal 
vaginal plug was detected. Treatments were continued until 1 day after detection 
of the vaginal plug. Each mated female was kept singly and was observed for 30 
days for evidence of pregnancy and parturition. After the 30 days, each 
previously CLZ treated female was re-mated with the same male that was used 
before to examine the reversibility of the compound and to attribute any 
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contraceptive effect to the test compound and not to any other factor such as 
female infertility and/or unsuccessful mating. A new control group of 10 mice, 
non-treated previously, was used for the re-mating experiment to address 
possible side effects of CLZ on animal pregnancy and litter size. All resulted 
offspring were observed until weaning and later some were superovulated and 
others were naturally mated to assess normal reproductive function. 
 
Statistics 
The Fisher exact test was used to determine the statistical differences of 
pregnancies among treatments. The Student T test was used to determine the 
average litter size differences between DMSO and water treated groups. 
The one way ANOVA was conducted to examine the differences among average 
litter sizes of re-mated animals and controls followed by the Games-Howell post-
hock test. Differences were considered significant at P<0.05. The statistical 
software of SPSS 14.0 (SPSS Inc., Chicago, IL, USA) was used to conduct all 
the statistical tests.  
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Figure 4.2. Effect of different treatments on pregnancy outcomes in naturally 
cycling mice. Note that none of the mice treated with CLZ produced pups in 
comparison to all of the control animals, which produced pups. Furthermore, 
DMSO did not affect pregnancy outcome (****<0.0001 using the Chi-square 
test). 
 
 
 
Results 
Figure 4.2 shows that none of the CLZ treated females conceived and produced 
offspring in comparison to all of the control females that conceived and  
produced offspring (P<0.0001). Furthermore, the average numbers of pups 
delivered by the dams that received water or DMSO were 8±1.4 vs. 6±1.6, 
respectively, P>0.05, indicating no direct detrimental effect of DMSO in this 
regard (Fig. 4.3). To assess CLZ reversibility, mice previously treated with CLZ 
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were re-mated 30 days after the first breeding. All of these females conceived 
and delivered normal pups and were not significantly different from controls 
(100% for each group). Figure 4.4 shows that there were no significant 
differences in the numbers of pups delivered among control dams and dams that 
were previously treated with 7.5 or 15mg CLZ, BID (7±1.18 vs. 6.41.35± vs. 
7.6±0.91, respectively, p=0.11). 
 
 
 
 
Figure 4.3. Effects of DMSO on litter size. Administration of the 0.15 ml DMSO 
vehicle control, bid, did not affect the litter size when compared to the water 
negative control (mean±STD, P>0.05 using the Student T test). 
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Figure 4.4. Reversibility effects of different CLZ treatments on litter size. The 
previously treated mice were re-mated with the same males used previously and 
allowed to complete the term. The number of pups per each female were 
counted and the average litter sizes were found similar among different groups 
(mean±STD, P>0.05 using the one way ANOVA).  
 
 
Discussion 
Previously, we found that CLZ was able to block oocytes from undergoing 
meiotic maturation in vitro and in superovulated mice (Chapter II and III). Here, 
we extended these observations to a more realistic state of contraception to 
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determine if the compound is able to block pregnancy. CLZ efficiently blocked 
pregnancy in naturally cycling female mice mated with fertile males that were not 
treated with CLZ. The notable contraceptive effect was reversible because all 
female mice previously treated with CZL became pregnant and had normal litter 
sizes. CLZ appears to be the safest of the PDE3-I compounds which, could be 
worthy of further evaluation as a non-steroidal contraceptive compound in other 
animal models. With the current steroidal contraceptive compounds, the benefits 
greatly outweigh the risks; nevertheless certain populations of people are 
vulnerable to undesirable health conditions and with family history of breast 
cancer and ischemic heart/cerebral diseases. Those conditions can be 
exacerbated with steroidal contraceptives, especially when used for long periods 
of time. This emphasizes the importance of further development of other 
alternative, non-steroidal, contraceptives suitable for those populations. The 
current steroidal contraceptive medications are known to precipitate side effects 
such as venous and arterial thromboembolism, hypertension, ischemic stroke. 
They are also associated with breast cancer (Beaber et al. 2012; Blanco-Molina 
et al. 2012; Hickson et al. 2011; Iatrakis et al. 2011; Tanis et al. 2001., White et 
al. 1994). It is suggested that CLZ shows fewer cardiovascular adverse effects 
than other PDE3-Is. CLZ, in comparison with other PDE3-I, has the ability to 
decrease adenosine uptake by muscle cells, endothelial cells, erythrocytes, and 
platelets. It also increases interstitial and circulatory adenosine concentrations 
that will moderately antagonize the positive intropic effect of CZL on the heart 
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(Liu et al. 2000 and 2001; Sun et al. 2002; Wang et al. 2001). Adenosine is 
thought to act on Adenosine-1 receptors (A1) on cardiac muscle leading to 
activation of Gi-protein and hence to inhibit adenylate cyclase (AC). Also, 
adenosine has been shown to attenuate protein kinase A-mediated increases in 
cardiac function and to decrease A-V automaticity and cardiotonicity of heart 
muscle produced by primary PDE3 inhibition via CZL. Adenosine acts on 
adenosine-2 receptors that activate Gs-protein to stimulate AC, and thus 
increases blood flow and inhibits platelet aggregation. Those effects are thought 
to be beneficial for women who use currently available contraceptives, which 
show cardiovascular and hematological concerns, especially in some 
populations (Liu et al. 2000 and 2001; Narayan et al. 2000; Nishi et al. 2000; 
Rang et al. 2007; Sun et al. 2002; Wang et al. 2001). 
The compound, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl) butoxy]-3, 4-dihydro-
2(1H)-quinolinone, is an FDA approved therapeutic and is prescribed for 
intermittent claudication disease under the brand name of Pletal®. It is also 
available as a generic drug; cilostazol. It is interesting to mention that CLZ 
manufacturers stated in their CLZ drug leaflet/pamphlet that “Cilostazol did not 
affect fertility or mating performance of female rats at doses as high as 1000 
mg/kg/day” (Otsuka America Pharmaceutical Inc. 2007). On the other hand, 
other PDE3-Is have been reported to block pregnancy of cycling rats and oocyte 
meiotic maturation in vitro and in superovulated mice and rats (Nogueira et al. 
2003a; Tsafriri et al. 1996; Wiersma et al. 1998). In our study, we observed a 
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complete block of pregnancy (100%) in the two CLZ treated groups of mice in 
comparison to 100% pregnancy in the negative and vehicle control groups. It is 
possible either that the reproductive response to CLZ in mice is different from 
that in rats and/or the manufacturer`s method of administration of CLZ, masked 
some outcomes and observations. In the present research, CLZ was 
administered in divided doses, dissolved in DMSO, whereas the manufacturer 
administration method was a dietary administration method as specified under 
the section of carcinogenesis, mutagenesis, and impairment of fertility in the 
CLZ drug leaflet (Otsuka America Pharmaceutical Inc. 2007). In our study, the 
animal weight average for all of the 40 animals used was 25.9± 2.1g. This 
means that each of our CLZ treated mice would have had to be given 
approximately 25.9mg/day of CLZ based on the manufacturer`s highest tested 
dose of 1000 mg/kg/day in comparison to our tested doses of 7.5 mg, bid 
(579mg/kg/day) or 15mg BID (1158.3mg/kg/day). The manufacturer tested dose 
was higher than our tested dose of 7.5 mg twice a day, while our other tested 
dose of 15 mg twice a day, was slightly higher than the manufacturer tested 
dose. In both cases, CLZ blocked pregnancy in mice. The CLZ doses in this 
experiment were based on the in vitro inhibitory concentrations of CLZ on mouse 
oocyte maturation, which were made to be similar to plasma concentrations in 
people who are taking CLZ (Chapters II and III). Moreover, the possible effect of 
DMSO on fertility was excluded as DMSO vehicle was administered to mice and 
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did not affect animal fertility or mating performance. Further investigations are 
needed to clarify the contraceptive differences of CLZ between mice and rats. 
Supplementation of the drug through diet may not be the best method to 
assess potential pharmacological and/or toxicological effects. Oral or parentera
l 
active ingredient administration ensures specific drug amount intake in animals 
whereas food-dietary supplementation may not. Animal food appetite may vary 
among animals and within the same animal during the treatment period. Animal
 
competitions and dominance/subordinance rank within a group can influence 
drug intake especially in multiple animal caging. An example of 
dominance/subordinance rank effects on housed animals was reported on 
housing male mice together.  Males with high levels of testosterone dominated 
groups and suppressed testosterone concentrations in the subordinate ones 
(Machida et al. 1981). Moreover, the more densely housed groups showed 
markedly reduced food consumption and slightly decreased mean body weights
 
(Chvédoff et al. 1980). This may have a considerable effect on animal appetites
 
and access to food and influence therapeutic concentration in animals when 
drug intake is an animal responsibility. Moreover, food and fluid consumption is 
variable during the estrous cycle, which may add another interruption to drug 
level when drug administration is supplemented with diet (Michell 1979; Reddy 
and Kulkarni 1999).  Rats showed elevated body weight and fat intake during 
diestrus when endogenous estrogens were reduced (Miceli and Fleming 1983).
  
On the other hand, behavioral indices of anxiety were found to increase during 
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estrus day/hours in rats and mice (Mora et al. 1996; Palanza et al. 2001). Those 
factors collectively justify concerns about test compound administration in the 
dietary food at which many factors such as estrous stage and anxiety affect food 
intake. Also, animal dominance/subordinance rank may exaggerate the unstable 
drug delivery.   
The New Drug Application (NDA) of CLZ reported to FDA indicated in the 
section of fertility study in rats that doses up to 1000 mg/kg/day, suspended in 
0.5% carboxymethylcellulose and administered once daily via gavage, did not 
block pregnancy significantly. The pregnancy rates in all CLZ treated rats were 
as low as 87.5% in comparison to 95.8% control treated females (United State 
Food and Drug Administration/Center for Drug Evaluation and Research 1981). 
The later experiment was similar to our experiment with its delivery and route of 
administration but different with its duration of treatment, daily frequency of 
administration, and vehicle used. While the NDA reported administration of CLZ 
in rats for 14 days prior to pairing and continued through the pairing period until 
day 7 of gestation, we administered CLZ to mice for a an average number of 3-4
 
days in both CLZ treatment groups (United State Food and Drug 
Administration/Center for Drug Evaluation and Research 1981). Development of 
tolerance or changes in drug metabolism of CLZ in prolong administration have 
not been reported; however, sex differences were found to affect 
pharmacokinetics of CLZ in rats but not in mice nor in dogs. Oral administration 
of CLZ in female rats showed a greater increase in area under the curve and 
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bioavailability of CLZ than in males. These effects in females were accompanied 
with a reduction in a total body clearance of CLZ of one-sixth in comparison to 
that in males (Akiyama et al. 1985; Kamada et al. 2011). The reported 
experiment in the NDA also indicated a daily single oral administration of CLZ in 
rats in comparison to our daily divided administration of CLZ (BID). Although 
CLZ was documented to have two main active metabolites, high protein binding 
of 95 to 98%, and an elimination half life of 11-13hr in humans, the compound 
was reported to have a half life of 3.7 h in female rats upon10 mg/kg oral 
administration of 14C-cilostazol (Lacy et al. 2011). From our previous studies, 
CLZ was predicted to have an elimination half life in female mice relatively 
similar to that in humans as administration of CLZ at the time of hCG in 
superovulated mice showed mixed ovulation of GV and fresh metaphase I 
oocytes. Moreover, multiple administration of CLZ at 4h pre-hCG and 2h post-
hCG or at the same time as hCG and 6h post-hCG showed ovulation of more 
than 90% of GV oocytes (chapter III). It is possible that single administration of 
CLZ in rats with relatively low half life of 3.7h may not be suitable to produce 
effects on fertility. 
 In addition, we used DMSO as a solvent and made CLZ solutions of 7.5 
or 15mg CLZ dissolved in 0.1 or 0.15ml DMSO, respectively. The vehicle used 
in the NDA was 0.5% carboxymehtycellulose, which is known to be a suspender 
agent; hence, using this vehicle makes a suspension of CLZ. DMSO is known to 
easily cross biological membranes without altering their integrity. One of the 
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properties of DMSO is that it can facilitate penetration of its dissolved 
ingredient(s) through biological membranes and consequently increase 
bioavailability and effectiveness of the dissolved ingredient(s) (Jacob and 
Herschler 1986; Rammler and Zaffaroni 1967). It is possible that DMSO 
increased CLZ intestinal absorption and augmented its bioavailability and 
therapeutic effect higher than that of carboxymehtycellulose. Collectively, this 
information of using daily divided doses of CLZ, rather than single dose, oral 
(gavage) administration, rather than drug-dietary administration, and CLZ 
solution (especially when dissolved in DMSO), rather than suspension, might 
have shown a similar contraceptive effect in rats. 
We are reporting here that CLZ is capable of blocking pregnancy in mice. 
Moreover, we have observed that CLZ was able to allow mice to ovulate 
significantly higher number of meiotically immature oocytes when CLZ was 
administered 9h pre-hCG to 2h post-hCG (Chapter III). Furthermore, we had 
observed previously that CLZ is capable of arresting oocyte meiotic maturation 
in vitro (Chapter II).  More evaluations are recommended to test the potential 
contraceptive effect and safety of CLZ using other animal models. 
 
Summary and conclusion 
• CLZ blocks pregnancy in naturally cycling mice 
• The evaluated doses are representative of those indicated in humans for 
therapeutic purposes. 
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• The doses evaluated by the manufacturer that did not impair fertility in 
rats were within our evaluated range of doses that impair fertility in mice. 
• Differences in the effects of CLZ on fertility between mice and rats may 
be due to physiological differences, or to time, frequency, and/or method 
of administration. 
• CLZ is a potential non-steroidal contraceptive that merits further 
evaluation 
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CHAPTER V 
 OVULATED IMMATURE OOCYTES HAVE ADVANCED DEVELOPMENTAL 
FEATURES IN COMPARISON TO OVARIAN IMMATURE OOCYTES IN MICE  
 
Overview 
Cilostazol was previously shown to result in ovulation of GV and/or MI oocytes in 
mice. Here, we compared cytoplasmic and meiotic maturation of ovulated GV 
and MI oocytes with corresponding ovarian GV and MI oocytes. Mice were 
superovulated and treated with CLZ to obtain ovulated GV and MI oocytes or 
were hyperstimulated to obtain ovarian GV oocytes. Some of the ovarian GV 
oocytes were incubated to obtain MI oocytes. Ovulated GV oocytes showed 
mainly chromatin configuration of surrounded nucleolus (SN) whereas the 
ovarian GV oocytes showed high rates of non-SN configuration (P<0.0001). 
Also, ovulated GV oocytes showed a higher incidence of peripheral cortical 
granules (CG) with intermittent domain in comparison to ovarian GV oocytes, 
which showed mainly a continuous peripheral CG distribution (P<0.001). 
Moreover, ovulated MI oocytes and MI oocytes obtained from in vitro maturation 
(IVM) of the ovulated GV oocytes had more normal spindles and chromosomes 
aligned at the metaphase plate than MI oocytes obtained from IVM of ovarian 
GV oocytes (P<0.003). Premature exocytosed CG were noted more in ovulated 
MI oocytes than other oocyte types (P<0.05). The GV oocytes were observed to 
have greater diameters than MI oocytes, and ovarian GV oocytes had greater 
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diameters than ovulated GV oocytes (P<0.007).  Finally, ovulated GV oocytes 
showed higher rates of GVBD, MII, and IVF than ovarian GV oocytes 
(P<0.0001). These results indicate that ovulated immature oocytes have 
advanced developmental levels and consequently a higher fertilization rate. 
These ovulated immature oocytes may substitute for immature ovarian oocytes 
and become an additional research resource. More studies are needed to 
address their ability to produce offspring.    
 
Introduction 
Collection of GV oocytes from antral follicles in hyperstimulated mice is a widely 
established technique for retrieval of GV oocytes. Investigators use their 
experience to select antral follicles under a microscope before puncturing the 
follicle. This is sometimes followed by screening of oocytes based on 
morphology and diameter and usually mouse oocytes of less than 65-70µm are 
excluded, especially when the research is not designed to study outcomes from 
different oocyte sizes. Shortcomings with the current technique include oocyte 
yield because the numbers of antral follicles do not always represent the 
numbers of the ovulated oocytes, in addition to the possibility of collecting 
oocytes that are not from antral follicles.  Moreover, ovarian GV oocytes show 
different types of chromatin configurations, CG and mitochondrial distributions, 
transcriptional activities, sizes, and others when collected after hyperstimulation 
(De La Fuente and Eppig 2001; Lee et al. 2006; Liu et al. 2005; Tokura et al. 
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1993; Wu et al. 2007; Zuccotti et al. 1995). Metaphase I oocytes are usually 
obtained via IVM of ovarian GV oocytes or directly from ovaries after 
administration of hCG or after the LH surge. The rate of MI oocytes obtained 
from IVM of ovarian GV oocytes depends on the type of culture medium, animal 
species, original size of GV oocyte/follicle used, cumulus cells state, and others 
(Choi et al. 2001; Curnow et al. 2010; Krisher 2004; Otoi et al. 2000; Schramm 
et al. 1993). Retrieval of MI oocytes directly from ovaries has the same 
limitations mentioned for the collection of ovarian GV oocytes, in addition to the 
need to determine the time course required for germinal vesicle breakdown 
(GVBD). While some investigators have reported a range of 4-9h post-ovulatory 
stimulus for GVBD to occur, others have reported times shorter than 3h for 
GVBD to occur depending on the mouse strain (Calarco et al. 1972; Edwards 
and Gates 1959; Hsieh et al. 2007; Kalous et al. 2006; Miao et al. 2004). In our 
experience, we have seen the time course of in vivo GVBD to vary within the 
same mouse strain at different times of the year even when mice are housed 
under controlled conditions.  
Oocytes, upon isolation from follicles, have the ability to undergo meiotic 
maturation (Pincus and Enzmann 1934). Meiotic maturation is believed to occur 
before cytoplasmic maturation. The lack of time synchronization between those 
two maturational components is believed to cause deficiencies in oocyte 
development and competence. Oocytes collected in stimulated cycles are more 
readily fertilized after preincubation than are oocytes inseminated immediately 
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after collection. This is thought to be because of cytoplasmic maturation 
subsequent to the polar body extrusion (Sundstrom and Nilsson 1988). 
Moreover, temporal arrest of spontaneous meiotic maturation of GV oocytes in 
vitro using PDE3-Is is found to increase oocyte meiotic competence (Albuz et al. 
2010; Nogueira et al. 2003a; Vanhoutte et al. 2007 and 2008).  
Previously, we showed that oral administration of CLZ in superovulated 
mice resulted in ovulation of oocytes of different meiotic stages based on CLZ 
dose, frequency of administration, and times of administration and collection of 
ovulated oocytes. Administration of CLZ before hCG injection allowed 
superovulated mice to ovulate MI oocytes whereas administration of CLZ in 
divided doses around the time of hCG injection resulted in ovulation of GV 
oocytes. We also found that when collection of immature oocytes was delayed, 
the ovulated oocytes were able to resume meiotic maturation in the oviduct, 
indicating a temporal arrest of oocytes at the GV stage (Taiyeb-Ridha et al. 
2011c). To define the quality of ovulated immature oocytes and to address the 
potential use of ovulated immature oocytes to substitute for ovarian immature 
oocytes, we studied meiotic and cytoplasmic maturation of the ovulated GV and 
MI oocytes and compared them with ovarian immature oocytes.   
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Materials and methods 
Animals 
Swiss Webster mice (8-10 weeks old) were purchased from Harlan Laboratories 
(Houston, TX, USA) and housed at the Texas A&M University Laboratory Animal 
Facility. Mice were under controlled temperature (23°C) and light/dark (14/10 h) 
cycle. Food and water were provided ad libitum. All experiments were approved 
by the Texas A&M University Institutional Animal Care and Use Committee.  
 
Reagents and chemicals 
Bovine hyaluronidase, monoclonal anti- β -tubulin antibody produced in mice, 
and ethidium homodimer were purchased from Sigma (St. Louis, MO, USA) and 
CLZ was purchased from LKT Laboratories (St. Paul, MN, USA).  Pregnant 
mare serum gonadotropin (Folligon®) and hCG (Chorulon®) were purchased 
from Intervet Inc (Summit, NJ, USA), and HTF (with or without HEPES) culture 
media for Murine IVF were obtained from Zenith Biotech (Guilford, CT, USA). 
Fluorescein lens culinaris agglutinin (LCA) and vectashield mounting medium 
with propidium iodide (PI) were purchased from Vector Laboratory (Burlingame, 
CA, USA). Alexa fluor 488 (ab`) 2 fragment of goat anti-mouse IgG (H+L), 
prolong gold DAPI mounting medium, and cell mask (red) were purchased from 
Molecular Probe (Grand Island, NY, USA). Lab-Tek II chamber slides were 
purchased from VWR International, LLC (Suwanee, GA, USA). 
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Experimental design 
Experiments were designed to test the following hypotheses: 1) CLZ results in 
ovulation of GV oocytes with higher rates of surrounded or partially surrounded 
chromatin than ovarian GV oocytes. 2) CLZ results in ovulation of GV oocytes 
with higher rates of cytoplasmic maturation than ovarian GV oocytes as 
evaluated by CG distribution. 3) Ovulated GV oocytes have faster meiotic 
development and higher fertilization rates than ovarian GV oocytes upon IVM. 4) 
CLZ results in ovulation of more MI oocytes with normal spindles and 
chromosomes aligned at the metaphase plates than in those obtained from IVM 
of ovarian GV oocytes. 5) CLZ results in ovulation of more MI oocytes with 
advanced cytoplasmic maturation than those obtained from IVM of ovarian GV 
oocytes as evidenced by CG distribution. 6) Size of oocytes, GV nuclei, and 
nucleolus vary between ovulated and ovarian oocytes. Figure 5.1 shows the 
design of the experiments that were conducted to test these hypotheses. 
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Figure 5.1. The experimental design for all the conducted experiments in chapter 
five. 
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Collection and processing of GV oocytes  
Groups of mice were hyperstimulated with 10 IU PMSG, ip, and GV oocytes 
from antral follicles were isolated using a 30G needle. Other groups were 
superovulated with 10 IU hCG 47h post-PMSG, ip. All superovulated mice 
received 7.5mg CLZ dissolved in 0.1ml DMSO (gastric gavage) at the same time 
as hCG and 6h post-hCG to allow ovulation of GV oocytes (Taiyeb-Ridha et al. 
2011c). The distended portion of the ampulla was punctured using a 26G needle 
to release oocytes. All GV oocytes (ovarian or ovulated) were collected in HTF 
medium with HEPES supplemented with 10% FBS and 4.2µM CLZ to block 
spontaneous maturation (Taiyeb-Ridha et al. 2011a). Some of the ovarian and 
ovulated cumulus enclosed GV oocytes were in vitro matured using HTF 
medium supplemented with 4.5% FBS for 1 or 3h, at 37°C and 5% CO2 in 
humidified air, to assess the time course and rate of GVBD.  
Some of the ovulated GV oocytes were denuded using 0.006% 
hyaluronidase for less than 2min. Those oocytes in addition to the ovarian 
denuded GV oocytes were fixed in 4% paraformaldehyde for 20 minutes 
followed by permeabilization using blocking washing solution (BWS) three times 
for 10 minutes each. The BWS consisted of 1X phosphate buffered saline (PBS) 
without Ca²+and Mg²+, 0.2% non-fat dry milk, 0.01% triton X-100, 2% FBS, 0.1M 
glycine, 2% heat–inactivated normal goat serum, and 0.02% sodium azide and 
was filtered through a 0.2µm membrane. The oocytes were incubated with 2% 
LCA (diluted in PBS) for 30 minutes at room temperature followed by three 
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washes with BWS (each of 10min). The oocytes were then loaded on Lab-Tek II 
chamber slides with prolong gold antifade reagent with DAPI or vectashield 
mounting medium with PI. The slides were stored in the dark at 4°C for at least 
three days to maximize signal: noise ratio. Oocytes were then analyzed for 
chromatin configuration and cortical granule distribution using a Carl Zeiss 
microimaging fluorescent inverted microscope (Stallion Digital Imaging 
Workstation; Thornwood, NY, USA) equipped with a C-Apochromat 63x water 
objective, a Photometrics CoolSnap HQ Camera, and slideBook software 
(Intelligent Imaging Innovations Inc.; Santa Monica, CA, USA). For FITC, an 
excitation filter of 470/20nm and emission filter of 505-530nm were used. Texas 
red data were collected with a 560/40 nm exciter and a 630/75nm filter. For cell 
mask, an excitation filter of 575/625nm and an emission filter of 660/710 were 
used to collect the data. DAPI data were collected with an excitation filter of 
365nm and emission filter of 445/50nm.  
Chromatin configurations were classified as follows: SN when chromatin 
formed a heterochromatin rim (intense fluorescent ring) condensed in close 
apposition with the nucleolus with or without few aggregates of condensed 
chromatin in the nucleoplasm area; partially surrounded nucleolus (PSN) when 
the nucleolus was partially surrounded by an opposed rim of condensed 
chromatin with few aggregates of condensed chromatin in the nucleoplasm area; 
and non-surrounded nucleolus (NSN) when chromatin was found non-
condensed and homogenously diffused in the germinal vesicle (De La Fuente 
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2006; Debey et al. 1993; Nogueira et al. 2003a). The distributions of CG in the 
cytoplasm of GV oocytes were classified as previously mentioned with slight 
differences. GV oocytes were classified as diffused CG when the CG were 
observed throughout the cytoplasm, whereas they were classified as peripheral 
CG when the CGs were aligned at the cortical and subcortical regions. When the 
peripheral CG showed a clear region or domain of faded and non-continuous 
peripheral green florescence, it was classified as peripheral CG with intermittent 
domain (CGID). When the CG were not observed, observed on a small portion 
at the periphery, or at the zona pellucida, they were classified as exocytosed CG 
(Liu et al. 2003; Liu et al. 2005). 
 
Collection and processing of MI oocytes 
To obtain ovarian MI oocytes, cumulus enclosed GV oocytes collected from the 
ovaries of hyperstimulated mice were incubated in HTF medium supplemented 
with 4.5%FBS for 6h at 37°C and 5% CO2 in humidified air. Superovulated mice 
were treated with 7.5mg CLZ at the same time as hCG to result in ovulation of 
MI oocytes (Taiyeb-Ridha et al. 2011c). In mice that ovulated GV oocytes (as 
described in the previous section), ovulated cumulus enclosed GV oocytes were 
incubated as described for 3h to obtain MI oocytes.  All resulted MI oocytes were 
fixed as described previously followed by blocking three times for 10 minutes 
each and incubation overnight with BWS at 4°C. On the next morning, oocytes 
were incubated for 1h at 37°C with 1st antibody of 1:200 monoclonal anti- β -
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tubulin produced in mice (diluted in PBS without Ca²+and Mg²+, 0.15 BSA and 
0.15 Tween 20). Oocytes were washed five times in the BWS (10 minutes each 
wash) and then incubated for 1hr at 37C with the 2nd antibody of 1:200 of Alexa 
fluor 488 (ab`) 2 fragment of goat anti-mouse IgG (H+L). Oocytes were washed 
three times with BWS (20 minutes each wash). Other MI oocytes resulting from 
ovulation or IVM of ovarian GV oocytes were fixed and analyzed for CG 
distribution as described for GV oocytes. All of those MI oocytes that were 
prepared to study the spindle and chromosomal normality and alignment or CG 
distribution were loaded on Lab-Tek II chamber slides with prolong gold antifade 
reagent with DAPI or vectashield mounting medium with PI and stored for at 
least three days before analyses. Metaphase I oocytes were considered 
organized if they showed a normal spindle of barrel shape and chromosomes 
aligned at the spindle equator. Oocytes that showed asymmetric spindles, 
multipolar, or displaced chromosomes were considered disorganized (Ridha 
Albarzanchi et al. 2008; Roberts et al. 2005; Sanfins et al. 2003). The analysis of 
CG distribution in MI oocytes was made similar to that described in GV oocytes 
with one exception. Only when the peripheral CGs showed a clear region of free 
domain of CG were MI oocytes classified as oocytes with peripheral CG with 
free domain (CGFD).    
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Diameter measurements of oocytes 
Vertical and horizontal diameters at the largest optical plane were obtained for 
GV and MI oocytes, GV nuclei, and nucleoli. Distances between the two poles of 
the spindles (spindle length) and of the equator of the spindles (spindle width) 
were obtained. Only those MI oocytes that displayed their spindles oriented 
along one optical plane (horizontal) were considered for length and width 
measurements. The use of Lab-Tek II slides provided a representative 
measurement for oocyte and organelle dimensions because the oocytes were 
not distorted or flattened by the coverslip and oocytes were allowed to maintain 
their spherical shape. 
 
Collection and processing of MII oocytes 
Ovulated or ovarian cumulus enclosed GV oocytes were incubated (as 
described above) for 10 or 14h to evaluate the time course and rate of MII 
oocyte maturation. For IVF experiments, ovarian cumulus enclosed GV oocytes 
were incubated for 14h whereas the ovulated cumulus enclosed GV oocytes 
were incubated for 10h followed by IVF. Sperm suspensions were prepared 
using spermatozoa collected from the tails of the epidiymides attached to ductus 
deferens from two mature males in HTF with HEPES culture medium 
supplemented with 4.5% FBS and incubated for 15 minutes at 37°C in order for 
spermatozoa to capacitate. Spermatozoa were added to the dish containing 
oocytes from three females to make a final concentration of two million 
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spermatozoa/ml in the oocyte medium (Taiyeb-Ridha et al. 2011b). The oocytes 
were removed from the spermatozoa after 6h and washed three times with HTF 
supplemented with 4.5% FBS before incubating for 24h using the same medium. 
Oocytes were assessed for 2 cell embryo rate after 24h of incubation.  
 
Statistical analyses 
The Chi-Square test, or when appropriate, the Fisher`s Exact test, was used to 
analyze the differences in chromatin configuration, CG distribution, GVBD, MII, 
IVF, oocyte distribution along different size measurements, and spindle and 
chromosome assembly rates between/among different oocyte types and origins. 
The One-Way ANOVA (followed by the Tukey post hoc test) and the 
Independent-Sample T tests were used to analyze the differences 
among/between oocyte, GV nucleus, and nucleolus diameters of different oocyte 
types. The One-Way ANOVA analysis followed by the Games Howell post hoc 
test was also used to evaluate differences of spindle lengths and widths among 
MI oocytes obtained from different origins. The threshold for significant 
difference was set at P<0.05, and SPSS® 14.0 software (SPSS Inc., Chicago, IL, 
USA) was used to carry out the statistical analyses. 
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Results 
Ovulated and ovarian GV oocyte evaluation 
Chromatin configuration 
The majority of ovulated GV oocytes showed SN chromatin configuration, 
with smaller proportions of oocytes demonstrating PSN configuration followed by 
NSN configuration (70.7% vs. 25.6% vs. 3.7%, respectively, P<0.0001, see 
Table 5.1). Conversely, the majority of ovarian GV oocytes showed NSN 
configuration as compared to PSN and NSN configurations (55% vs. 24.2% and 
20.8%, respectively, P<0.0001). Ovulated GV oocytes showed a higher rate of 
SN configuration when compared to the ovarian GV oocytes (P<0.0001) 
whereas NSN configuration was noted more in ovarian GV oocytes than 
ovulated GV oocytes (P<0.0001). The rate of PSN configuration was not 
different between the two oocyte types. Table 5.1 shows chromatin configuration 
rates of ovulated and ovarian GV oocytes.  
 
 
 
Table 5.1. Chromatin configurations of ovulated and ovarian GV oocytes.   
Chromatin Configuration Ovulated GV Ovarian GV 
SN (%) 70.7**** 20.8 
PSN (%) 25.6 24.2 
NSN (%) 3.7 55**** 
Total number of oocytes 82 120 
Sn: surrounded nucleolus, PSN: partial surrounded nucleolus, NSN: non-surrounded nucleolus. 
Values with asterisks are significantly different along each row where ****<0.0001. 
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Cortical granule distribution 
Ovulated GV oocytes showed mainly peripheral CG with or without 
intermittent domain more than other distributions (P<0.003, see Table 5.2). 
These two distributions were followed by diffused CG, which was in turn followed 
by exocytosed CG (15.85% vs. 1.21%, respectively, P<0.0001). In ovarian GV 
oocytes, peripheral CG was the dominant distribution (P<0.0001), and diffused 
CG was the next most common, with other distributions being less common 
(P<0.0001). Comparing the CG distribution between the two types of GV 
oocytes revealed that the ovarian GV oocytes have a higher incidence of 
peripheral CG distribution whereas the ovulated GV oocytes have a higher 
incidence of peripheral CGID (P<0.001). Table 5.2 shows the CG distribution of 
ovulated and ovarian GV oocyte types. 
 
 
 
Table 5.2. Cortical granule distributions of ovulated and ovarian GV oocytes.  
 Ovulated GV Ovarian GV 
Diffused CG (%) 15.85 22.68 
Peripheral CG (%) 47.56 71.42*** 
Peripheral CGID (%) 35.36**** 4.2 
Exocytosed CG (%) 1.21 1.68 
Total number of oocytes 82 119 
CG: cortical granules, CGID: cortical granules with intermittent domain, ECG: exocytosed 
cortical granules. Values with asterisks are significantly different along each row where 
***<0.001, ****<0.0001. 
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Coincidence of chromatin configuration and CG distribution 
 Analysis of CG distributions (as an indicator of cytoplasmic maturation) 
among the different chromatin configurations (as an indicator of meiotic 
development) was conducted. It was observed that the ovarian GV oocytes 
whether of SN, PSN, or NSN chromatin configuration had peripheral CG more 
than other distributions (P<0.03, Fig. 5.2A). It is concluded that the CG 
distribution in ovarian GV oocytes is independent of chromatin configuration 
because all the different configurations showed mainly CG distributed at the 
periphery of the oocytes. 
Ovulated GV oocytes of SN configuration displayed mainly peripheral CG 
with or without intermittent domain compared to other distributions (P<0.0001, 
Fig. 5.2B), whereas ovulated GV oocytes of PSN configuration did not show a 
dominant distribution of CG. Since only three ovulated GV oocytes displayed 
NSN configuration (one for each of diffused CG, peripheral CG, or peripheral 
CGID) out of 81 ovulated GV oocytes, they were excluded from this comparison. 
These results indicate that the ovulated GV oocytes of SN configuration are 
relevant to both peripheral CG with or without intermittent domain. Moreover, the 
advanced stage of CGID, which is a sign of the beginning of formation of the 
free domain that usually occurs in MI oocytes, indicates that GV oocytes of SN 
configuration begin to initiate meiotic maturation. Increasing the number of 
ovulated GV oocytes with PSN configuration (more than 21 oocytes) might 
provide an accurate interpretation for the lack of a similar trend with ovulated GV 
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oocytes. Figure 5.3 shows photos of different chromatin configurations and CG 
distributions of ovarian and ovulated oocytes.  
 
 
 
 
 
  
 
Figure 5.2. Ovarian and ovulated GV oocytes of different configurations of chromatin 
within different distributions of cortical granules (CG). A: ovarian GV oocytes.  The 
numbers of oocytes that were considered for both chromatin and CG configurations were 
as follows: SN= 24, PSN= 29, NSN= 66. Different superscripts of the same chromatin 
configuration along different distributions of CG are significantly different P<0.03. B: 
ovulated GV oocytes. The numbers of oocytes that were considered for both chromatin 
and CG configurations were as follows: SN= 60, PSN= 21. Only 3 ovulated GV oocytes 
were with NSN configuration and were not considered in this graph (1 GV oocyte for each 
of diffused CG throughout cytoplasm, peripheral, or peripheral CG with intermittent 
domain). P<0.0001. 
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Figure 5.3.  Ovulated and ovarian immature oocytes with different chromatin and CG levels of 
maturation. A-J are pictures of immature ovarian oocytes. A: is a GV oocyte with NSN 
configuration detected with PI. Note the non-condensed and homogenously diffused chromatin 
in the germinal vesicle. B: is a GV oocyte with PSN configuration detected with DAPI. Note that 
not all of the chromatin has condescended. C: is a GV oocyte with SN configuration. Note the 
formation of the rim with 2 condescended chromatin foci. D: is a GV oocyte with PSN and 
diffused CG. Note the distribution of CG throughout the cytoplasm. E-F: is a GV oocyte with NSN 
configuration (E) and diffused CG (F). G: is the merged picture of E and F. H: is a GV oocyte 
with SN configuration and peripheral CG. Note the distribution of CG at the periphery. I-J: are MI 
oocytes obtained form IVM of ovarian GV oocytes. Note the peripheral CG distribution (I) and 
exocytosed CG (J). K-T: are pictures of ovulated immature oocytes. K: is a GV oocyte with NSN 
configuration. L: is the merged picture of K. M-N: is a GV oocyte with PSN configuration (M) and 
diffused CG (N). O: is the merged picture for M and N. P: is a picture for two GV oocytes of SN 
configurations and peripheral CG. Q-R: are GV oocytes of SN configurations and peripheral 
CGID. S: is an ovulated MI oocyte with peripheral CGFD. T: is an ovulated MI oocyte with 
exocytosed CG. Note the distribution of CG at the zona pellucida while the oocyte is stained with 
the cell mask (red). 
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Meiotic maturation 
Scoring of ovulated and ovarian cumulus enclosed GV oocytes after 1h of 
IVM showed a higher incidence of GVBD in ovulated oocytes than ovarian 
oocytes (90.9% vs. 10%, respectively, P<0.0001, Table 5.3). Actually, we 
observed GVBD in ovulated GV oocytes happening within a few minutes when 
CLZ was not added to the initial collection medium (data not included). Scoring 
of cumulus enclosed oocytes incubated for 3h showed 99% GVBD in ovulated 
GV oocytes and 86.3% GVBD in ovarian GV oocytes (P<0.0001). We further 
extended the IVM for 10h and scored other groups of cumulus enclosed oocytes 
and found that 97.27% of the ovulated GV oocytes had emitted the 1st polar 
body whereas 61.6% of the ovarian GV oocytes had emitted the 1st polar body. 
Extending the incubation to 14h in other groups of GV oocytes continued to 
show low rates of MII oocytes resulting from ovarian GV oocytes in comparison 
to those observed in ovulated GV oocytes (P<0.0001). Incubation beyond 14h 
did not improve MII rate for ovarian cumulus enclosed GV oocytes (data not 
shown). Therefore, ovarian or ovulated cumulus enclosed GV oocytes were 
incubated for 14 or 10h, respectively, followed by IVF. The ovulated GV oocytes 
showed a higher rate of 2 cell embryos than ovarian GV oocytes (84.81% vs. 
68.31%, respectively, P<0.0001, Table 5.3).  
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Table 5.3. Meiotic maturation and in vitro fertilization rates of ovulated GV and ovarian GV 
oocytes. 
 Ovulated GV, n (%) Ovarian GV, n (%) 
GVBD-IVM/1h 120/132 (90.9)**** 12/120 (10) 
GVBD-IVM/3h 92/93 (99)*** 88/102(86.3) 
MII- IVM/10h 143/147 (97.27)**** 74/120 (61.6) 
MII- IVM/14h 99/100 (99)**** 94/112 (84) 
IVF 134/158 (84.81)**** 138/202 (68.31) 
GVBD: germinal vesicle breakdown, IVM: in vitro maturation, MII: metaphase II, IVF: in vitro 
fertilization. Values with asterisks are significantly different along each row where ***<0.001 
and ****<0.0001. 
 
 
 
Ovulated and in vitro matured MI oocytes 
Spindle and chromosomal organization 
Ovulated MI or MI oocytes resulting from IVM of ovulated GV oocytes 
showed higher percentages of normally organized spindles with chromosomes 
aligned on the metaphase plate than those of MI oocytes obtained from IVM of 
ovarian GV oocytes (88.4% and 93.9% vs. 70%, respectively, P<0.003, Fig. 
5.4A). We evaluated the length and width of spindles only in oocytes that were 
classified normal. We found the spindle width of MI oocytes obtained from IVM 
of ovarian GV oocytes longer than those in MI oocytes obtained from IVM of 
ovulated GV oocytes and ovulated MI oocytes (12.7±3.8µm vs. 11.2±2.2µm and 
9.9±3µm, mean±SD, respectively, P=0.002, Fig. 5.4B). The spindle lengths were 
not significantly different (P=0.33). Figure 5 shows MI oocytes with different 
spindle and chromosomal organizations. 
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Figure 5.4. Spindle and chromosomal organizations and dimensions in MI oocytes 
collected from different protocols. A: Ovulated MI oocytes (95 oocytes) and MI oocytes 
(33 oocytes) obtained from IVM of ovulated GV oocytes showed higher rates of 
organized spindles with aligned chromosomes at the spindle metaphase plate  when 
compared  to MI oocytes (90 oocytes) obtained from IVM of ovarian GV oocytes.  
Different superscripts are significantly different (P<0.003, Tukey post hoc test). B: 
Spindle length did not vary significantly among MI oocytes from different origins but MI 
oocytes obtained from IVM of ovarian GV oocytes showed wider spindles at the 
equator than other MI oocyte types (mean±SEM). Different superscripts of spindle 
length or width along different MI oocyte types are significantly different (P=0.003, 
ANOVA-Games Howell post hoc test).  
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Figure 5.5. Various spindle and chromosomal organizations of MI oocytes obtained from 
different methods. A, D, and G are MI oocytes collected from IVM of ovarian GV oocytes. A 
displays normal spindle and chromosomal organization whereas D and G show abnormal 
spindle morphology. B, E, and H are MI ovulated oocytes. B and E show normal spindle and 
chromosomal organization whereas H has chromosomes that are not aligned at the spindle 
equator. C, F, and I display MI oocytes collected from IVM of ovulated GV oocytes. C and F 
display normal spindle and chromosomal organization whereas I shows an MI oocyte with 
abnormal spindle and chromosomes displaced from the equator.  
 
Cortical granule distribution 
MI oocytes obtained from IVM of ovarian GV oocytes showed a high rate 
of peripheral CGFD (P<0.003) followed by peripheral CG (P<0.005) when 
compared to other distributions (Table 5.4). Ovulated MI oocytes showed a 
similar trend but the rate of oocytes with exocytosed CG was significantly higher 
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than for oocytes with diffused CG (11.6% vs. 2.1%, P=0.01). The distribution of 
CG between the two MI oocyte types were similar except for the high incidence 
of exocytosed CG in ovulated MI oocytes in comparison to MI oocytes obtained 
from IVM of ovarian GV oocytes (11.6% vs. 3.9%, respectively, P<0.05, Table 
5.4). 
 
 
 
Table 5.4. Cortical granule distributions of ovulated MI oocytes and MI oocytes obtained from 
IVM of ovarian GV oocytes.  
 MI oocytes from IVM of 
ovarian GV oocytes   
Ovulated MI  
oocytes 
Diffused CG (%) 7.8 2.1 
peripheral CG (%) 29.4 26 
Peripheral CGFD (%) 58.8 57.3 
ECG (%) 3.9 11.6* 
Total number of oocytes 51 96 
CG: cortical granules, CGFD: cortical granules with free domain, ECG: exocytosed cortical 
granules. Values with asterisks are significantly different along each row where *<0.05 
 
 
 
Diameter measurements of oocytes 
A majority of the ovulated GV oocytes have diameters within 70.1-80µm 
followed by diameter ranges of 60.1-70µm and 80.1-90µm (P<0.002) followed 
by other sizes (P<0.0001, Fig. 5.6A).  For ovarian GV oocytes retrieved from 
antral follicles, more oocytes with a diameter range of 90.1-100µm were 
observed than other diameter ranges (P<0.01) but was similar to oocytes  
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Figure 5.6. Diameter distribution of GV and MI oocytes obtained from different protocols. A: 
ovarian GV oocytes collected from antral follicles had a wider diameter size range of 50-100µm 
than ovulated GV oocytes that had a diameter size range of 60-90µm. B: note the uniform 
diameter size of ovulated MI oocytes of 50-60µm when related to MI oocytes obtained from IVM 
of ovulated GV oocytes (50-80µm) and ovarian GV oocytes (50-90µm). Data points with different 
superscripts are significantly different along each curve line (P<0.05). 
  
 
 
observed with sizes of 60.1-70µm, which in turn was significantly different 
from oocyte diameter ranges from 45-60µm and 100.1-110µm (P<0.002). More 
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oocytes with size range 50.1-60µm were counted than oocytes with sizes of 45-
50µm and 100.1-110µm (13.1% vs. 4% and 5%, P<0.05). These data indicate 
that the ovulated GV oocytes were within a narrower size range (60-90µm) than 
ovarian GV oocytes, which showed a wider size range of 50-100µM. Also, it is 
suggested that oocytes of small size of 45-60µm may be found in antral follicles 
since ovulated oocytes of similar size range were also found but with much 
lower frequencies (17.1% and 2.5%, respectively, P=0.001, Fig. 5.6A).  
Ovulated MI oocytes were found to be within the size range of 50-80µm 
followed by other size ranges (P<0.002) whereas MI oocytes resulting from IVM 
of ovulated GV oocytes showed mainly sizes within 50.1-60µm followed by other 
size ranges (P<0.0001, Fig. 5.6B). Metaphase I oocytes resulting from IVM of 
ovarian GV oocytes were more frequent within size ranges of 50.1-60µm and 
70.1-90µm than other size ranges (P<0.002). These data revealed that while the 
ovulated MI oocytes and MI oocytes resulting from IVM of ovulated GV oocytes 
are more abundant within a continuous and narrow size range of 50.1-80µm or 
50.1-60µm, respectively, the MI oocytes resulting from IVM of ovarian GV 
oocytes displayed a high number of oocytes within a non-continuous size range 
of 50.1-60µm and then 70.1-90µm (Fig. 5.6B). 
Although ovulated GV oocytes with small diameters of 45-60µm were 
detected but with lower rates than that in ovarian GV oocytes collected from the 
antral follicles, the overall comparison between ovulated and ovarian GV oocyte 
sizes did not include oocytes of less than 60µm in diameter to exclude any 
 109 
 
possible negative impact of the small sizes of oocytes on oocyte quality from 
either source. Overall, GV oocytes whether ovulated or ovarian were observed 
to have considerably greater diameter than MI oocytes whether ovulated or 
obtained from IVM of ovulated or ovarian GV oocytes (P<0.007, Fig. 5.7A). This 
indicates that initiation of meiosis is associated with reduction of oocyte size. 
Moreover, the ovarian GV oocytes were found to have greater diameters than 
ovulated GV oocytes (82.02±12.6 vs. 76.7±8.26µm, mean±SD, P<0.007), which 
may refer to the readiness of the ovulated GV oocytes to undergo GVBD and to 
progress to the MI stage, especially, ovulated GV oocytes had higher rates of 
meiotic development within a shorter duration of time in comparison to ovarian 
GV oocytes (Table 5.3). The same observation was noted between MI oocytes 
obtained from IVM of ovulated GV oocytes and other MI oocyte types, which 
may be attributed to the same reason. Also, we observed that the diameters of 
GV nuclei in ovulated GV oocytes were smaller than those in ovarian GV 
oocytes (27.42±3.62 vs. 30.27±10.26µm, mean±SD, P=0.007, Fig. 5.7B), which 
may also indicate GV oocytes that had started to undergo GVBD. Conversely, 
the nucleolus diameters in ovulated GV oocytes were found to be greater than 
those in ovarian GV oocytes (10.74±0.83 vs. 10.21±1.36µm, mean±SD, 
P=0.001, Fig. 5.7C). 
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Figure 5.7. Oocyte, GV, and nucleolus diameters of different oocyte types. A: Diameters of 
oocytes of different origins and meiotic stages. Data points with different superscripts are 
significantly different (P<0.007). B: GV diameters of ovulated and ovarian GV oocytes (P=0.007). 
Nucleolus diameters of ovulated and ovarian GV oocytes (P=0.001). 
 
 
 
The distributions of oocyte, GV, and nucleolus diameters of ovarian and 
ovulated GV oocytes among different chromatin configurations were studied. We 
noted that the diameter of ovarian GV oocytes started to decrease significantly 
when they displayed SN configuration in comparison to PSN and NSN 
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configurations (70.12 vs. 87.52 and 84.52µm, respectively, P<0.0001, Fig. 5.8) 
whereas there was no significant difference in the diameter of ovulated GV 
oocytes displaying SN or PSN configurations (75.3 and 79.11µm, respectively). 
Only three ovulated GV oocytes showed a NSN configuration, which were 
considered not representative to be considered in this comparison. Collecting 
higher numbers of ovulated GV oocytes with NSN configuration might confirm a 
similar trend to that observed in ovarian GV oocytes, if they display greater 
diameters. Interestingly, those three ovulated GV oocytes with NSN 
configuration showed greater diameter of 83.53±4.15µm (mean±SEM). 
The GV nuclei of ovarian oocytes among the different configurations did not vary 
but ovulated GV oocytes of PSN configuration had greater diameters of GV 
nuclei than those of the SN configuration (29.15 vs. 26.64µm, P=0.007). This 
size reduction in nuclei of the ovulated SN oocytes may relate to the readiness 
of GV nuclei in the ovulated GV oocytes to undergo GVBD as confirmed by the 
short duration required for GVBD (Table 5.3). Finally, nucleolus diameters were 
not different among different chromatin configurations from both oocyte types, 
indicating that the nucleolus size of GV oocytes does not depend on different 
chromatin configurations.    
 
 112 
 
 
Figure 5.8. Oocyte, GV, and nucleolus sizes of ovulated and ovarian GV oocytes of different 
chromatin configurations. Different superscripts indicate significant differences among the 
different chromatin configurations. Data are presented as mean±SEM. 
 
 
 
Discussion 
The purpose of the present study was to evaluate the quality of ovulated 
immature oocytes and their potential use as alternatives to ovarian immature 
oocytes. We observed in this study that ovulated GV oocytes have advanced 
meiotic and cytoplasmic maturations when compared to ovarian GV oocytes. 
The advanced meiotic maturation of ovulated GV oocytes was evidenced by a 
high rate of chromatin configuration of SN type and short duration of GVBD (less 
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than 1h). The advanced cytoplasmic maturation of the ovulated GV oocytes 
evoked a high incidence of peripheral CGID, in addition to the continuous and 
peripheral CG. Such ovulated GV oocytes of SN configuration and peripheral 
CG with or without intermittent domain correlated with higher rates of GVBD, MI, 
MII, and IVF when compared to ovarian GV oocytes, which showed mainly NSN 
configuration and peripheral CG distribution. This state of peripheral CGID 
precedes the formation of the free domain in the peripheral CG and indicates 
that the ovulated GV oocytes have started to initiate the free domain in the 
peripheral CG; a state that is observed in MI oocytes. This further indicates that 
cytoplasmic maturation, to the extent that CG distribution is a representative 
indicator of cytoplasmic maturation, is independent from meiotic maturation and 
that it can precede meiotic maturation when ovulation of GV oocytes is induced. 
On the other hand, ovulated MI oocytes and MI oocytes obtained from IVM of 
ovulated GV oocytes showed higher rates of normal spindles with chromosomes 
assembled at the metaphase plates than those of MI oocytes obtained from IVM 
of ovarian GV oocytes, indicating that ovulated MI and MI oocytes from ovulated 
GV oocytes have higher quality. Moreover, the CG distribution between ovulated 
MI oocytes and MI resulting from ovarian GV oocytes were similar except with a 
considerable increase of exocytosed CGs in the ovulated MI oocytes. We 
observed a reduction in oocyte size upon initiation of meiotic maturation and 
ovulation. Also, ovulated immature oocytes have convenient features such as 
ease of retrieval, reduced time for retrieval, high yield, and being representative 
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of the cohort of ovarian follicles that ultimately undergo ovulation. It was also 
noted that ovulated immature oocytes have more uniform sizes when compared 
to ovarian oocytes retrieved from the antral follicles, suggesting that oocytes 
collected from antral follicles do not always represent oocytes that would be 
ovulated.  
Many factors such as oocyte/follicle size and age have been found to 
influence chromatin configuration of oocytes (Scharmm et al. 1993; Zuccotti et 
al. 1995). In this study, ovulated GV oocytes were influenced by PMSG, hCG, 
and CLZ; and consequently with changes in the cAMP and GJC levels. Mice 
primed with PMSG were found to increase GV oocytes with SN configuration 
(Mattson and Albertini 1990; Tan et al. 2009; Zuccotti et al. 1995). The IVM of 
such oocytes showed higher meiotic maturation and competence with a lower 
level of autoactivation than GV oocytes of NSN configuration (Zuccotti et al. 
1998 and 2002). Higher proportions of ovarian GV oocytes of bitches had 
grouped chromatin (comparable to SN) when isolated after the LH peak than 
before the LH peak (Reynaud et al. 2009). Similarly, the SN:NSN ratio of ovarian 
GV oocytes in mice increased after hCG-induced ovulation (Bouniol Baly et al. 
1999). These data indicate that NSN immature oocytes are not ready to be 
ovulated and need to reach the SN configuration. Moreover, it was suggested 
that the SN oocytes that failed to ovulate had   undergone atresia. This is further 
confirmed with a high proportion of SN oocytes in aged mice. On the other hand, 
it is speculated for NSN oocytes that fail to reach SN configuration are to be 
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recruited following the LH surge (Tan et al. 2009; Zuccotti et al. 1998 and 2005). 
In addition to the gonadotropin effects, active GJC between oocytes and 
follicular cells are believed to maintain high levels of intraoocyte cAMP. Such a 
state was found to be associated with oocytes with low meiotic development and 
NSN configuration (Lodde et al. 2007). Conversely, interrupting the GJC was 
found to condense the chromatin and cease the RNA synthesis (Luciano et al. 
2011). On the other hand, hCG/LH is known to disrupt GJC, decrease oocyte 
cAMP, and induce SN configuration (Bouniol Baly et al. 1999; Hashimoto et al. 
1988; Isobe et al. 1998). In regard to PDE3-I effects on chromatin 
configurations, arresting oocytes at the GV stage via a PDE3-I was found not 
only to increase intraoocyte cAMP levels but also SN configuration of oocytes 
(Nogueira et al. 2003a; Vanhoutte et al. 2007). These observations collectively 
indicate that inhibition of GJC reduces cAMP outflow from the granulosa cells to 
oocytes and increases the tendency of chromatin to organize in the SN 
configuration. Moreover, arresting oocytes at the GV stage via a PDE3-I 
elevates intraoocyte cAMP and enhances SN configuration of oocytes. It is 
suggested that follicular cAMP, when having active GJC, causes oocyte 
chromatin to have NSN configuration, and when intraoocyte cAMP increases, 
results in SN configuration. This is further supported by our previous and present 
results that showed that ovulated GV oocytes, which lack GJC and have 
moderate cAMP levels, have a SN configuration whereas ovarian GV oocytes, 
which are surrounded by compact cumulus cells and have high cAMP levels, 
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have NSN configuration (Chapter III). We are suggesting the following scenario 
for the high incidence of SN with ovulated GV oocytes and NSN configuration 
with ovarian GV oocytes: priming mice with PMSG increased oocytes with SN 
configuration. This is further potentiated by hCG administration that disrupts 
GJC and reduces cAMP flow to oocytes. Finally, administration of CLZ inhibits 
PDE3, arrests oocytes at GV, and increases the intraoocyte cAMP, which 
exacerbates the SN occurrence in ovulated GV oocytes. Those factors 
collectively aid to synchronize GV oocytes at SN configuration and consequently 
increase meiotic and developmental competence.  
The distribution of CG has been used as a criterion to evaluate 
cytoplasmic maturation in addition to mitochondrial distribution and cytosolic 
redox state (Curnow et al. 2010; Dumollard et al. 2007; Liu et al. 2005; Miao et 
al. 2009; Miyara et al. 2003; Sha et al. 2010,). Liu and coworkers suggested a 
role for MI chromosomes to induce free domain in the peripheral CG because 
they found MI stage preceded the initiation of free domain and no peripheral free 
domain was observed in GV oocytes arrested with PDE3-I up to 15h in vitro (Liu 
et al. 2005). Here, we observed CGID in ovulated GV oocytes indicating that 
formation of peripheral CGFD may not be dependent of meiotic maturation. 
Similar to chromatin configuration, the CG in our ovulated GV oocytes were 
exposed to CLZ and gonadotropins and their consequences. An increase of 
gonadotropin concentrations in the culture medium resulted in an increase in CG 
migration toward the periphery (Sha et al. 2010). Collection of oocytes post-hCG 
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in superovulated mice showed shorter durations of time required to form 1st or 
2nd free domain in the peripheral CG in comparison to oocytes matured in vitro 
(Liu et al. 2005). Moreover, Stoker and coworkers showed that delaying 
ovulation in rats by one day via suppression of the LH surge showed abnormal 
CG patterns (Stoker et al. 2003). The latter study showed the essential role of 
the ovulatory stimulus on CG distribution as an abnormal CG pattern was 
observed when follicular fully grown GV oocytes had delayed GVBD due to lack 
of LH effect. In the present study, oocytes were arrested at the GV stage without 
interfering with hCG/LH effects and were showing advanced stages of 
distribution of CG in comparison to ovarian GV oocytes. These data indicate that 
LH/hCG aids to control CG distribution and may be the factor for the formation of 
the intermittent domain in ovulated GV oocytes. In regard to the effect of PDE3 
inhibition on CG distribution, Liu and colleagues showed that the arrest of 
oocytes with hypoxanthine allowed CGs to align at the periphery in only a 
portion of the oocytes when incubated up to 15h, in agreement with previous 
reports (Duque et al. 2002; Liu et al. 2005; Nogueira et al. 2003b). This suggests 
a role for elevated cAMP that does not support CG migration. These data along 
with our observations lead us to conclude that CG distribution is controlled by 
the ovulatory stimulus that overcomes the inhibitory role of cAMP on CG 
distribution. Furthermore, both advanced cytoplasmic and meiotic maturation, as 
evidenced by peripheral CGID and SN configuration, respectively, can result in 
ovulated GV oocytes undergoing GVBD within an hour, mature into MII stage 
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with high yield and within 10h, and associate with high IVF rates. On the other 
hand, ovarian GV oocytes that had peripheral CG distribution in addition to 
dominant NSN configuration require approximately 3h for GVBD to be 
completed in all oocytes and matured into MII stage in low yield and within 14h. 
These ovarian GV oocytes were associated with low IVF rates when compared 
to ovulated GV oocytes.  
Interestingly, some of the ovulated MI oocytes showed CG activation. We 
suggest that those oocytes had undergone a premature exocytosis. Exocytosis 
of CG is observed in aged, activated, or fertilized MII oocytes (Liu et al. 2003; 
Miao et al. 2009; Xu et al. 1997). Although the ovulated MI oocytes from mice 
treated with 7.5mg CLZ at the same time as hCG were found to have 
exocytosed CG (as reported in this study), another study showed the IVF rate of 
ovulated MI oocytes, resulting from animals treated with 7.5mg CLZ at 4 or 7h 
pre-hCG, was higher than that of ovulated MII oocytes from non-treated mice 
(Taiyeb-Ridha et al. 2011b). It is suggested that the premature exocytosed CGs 
in ovulated MI oocytes obtained from mice treated with 7.5mg CLZ at the same 
time as hCG does not influence the IVF rate because only 11.6% of MI oocytes 
showed exocytosed CG counterbalanced by a high rate of organized spindle 
and chromosomes and potential positive effect of MI oocyte uniform size. It is 
also suggested that ovulated MI oocytes from mice treated at 4h or 7h pre-hCG 
with CLZ have low levels of premature exocytosed CG and consequently higher 
IVF rates.  
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It was observed in this study that the GV oocytes (whether ovulated or 
ovarian) started to decrease in size when transitioning to MI oocytes probably 
due to utilization of proteins, substrates, factors, and nutrients in the cytoplasm 
(Gandolfi and Gandolfi 2001; Watson 2007) and/or due to GVBD and 
consequent size shrinkage. If MII oocytes are found to be smaller than MI 
oocytes, the considerable decrease in size of MI oocytes obtained from IVM of 
ovulated GV oocytes in comparison to other MI oocytes could be attributed to MI 
oocytes that are closer to emitting the 1st polar body, form a perivitelline space, 
and/or further utilize factors and proteins in the cytoplasm. This is further 
supported by the fact that ovulated GV oocytes required 10h to transition to MII 
oocytes whereas ovarian GV oocytes required a longer period. Moreover, 
ovulated MI oocytes from mice treated with CLZ at 4 or 7h pre-hCG required 3 
or 6h, respectively, to extrude the 1st polar body (Taiyeb-Ridha et al. 2011b).  
Tartia and colleagues found that the reduction in oocyte size was 
completed during the MI stage; approximately 10h post-hCG. This reduction in 
oocyte size is controlled through accumulation of glycine, which provides 
intracellular osmotic support to control cell volume homeostasis during size 
reduction. Glycine accumulation was found to be mediated through glycine 
transporters (GLYT1). Activation of GLYT1 follows the ovulatory stimulus and 
the initiation of meiotic maturation but was found to be quiescent in freshly 
isolated GV oocytes. Interestingly, arresting oocytes at the GV stage in vitro 
using cAMP agonist compounds showed both size reductions and activation of 
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GLYT1, indicating that the GLYTI transporter does not require meiosis or hCG 
when spontaneous maturation is blocked (Tartia et al. 2009). It is hypothesized 
that ovulated GV oocytes were able to reduce size more than ovarian GV 
oocytes because ovulated GV oocytes have active CLYT1 due to the hCG 
trigger, arrest of meiosis induction. Such oocytes are believed to be close to 
initiation of meiosis as they are characterized by advanced levels of maturation 
and short duration of GVBD. Ovarian GV oocytes may lack all of those triggers 
that are required to activate the mechanism that regulates cell volume 
homeostasis during size change and consequently have greater diameters than 
ovulated GV oocytes. 
As a concept, oocyte maturation and competence were reported to have 
a positive correlation with oocyte size (Anquita et al., 2007, Comizzoli et al., 
2011; Hirao et al., 1993; Otoi et al., 2000; Raghu et al., 2002). Here, we 
observed that ovarian and ovulated GV oocytes reduce their size upon meiosis. 
Therefore, we add to this concept additional information, that is, although oocyte 
competence is positively related to oocyte size, immature oocytes will have 
reduced their size upon meiosis. Also, it is suggested that relatively smaller 
immature oocytes collected from ovaries after an ovulatory stimulus could mean 
collection of oocytes with advanced developmental competence when compared 
to greater immature oocytes collected from ovaries after the stimulus. This is 
supported by the fact that ovulated GV oocytes revealed an advanced meiotic 
and cytoplasmic development and higher fertilization rate and were smaller in 
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size when compared to the ovarian GV oocytes that were greater in sizes and of 
lower meiotic and cytoplasmic maturation and fertilization rates. Therefore, the 
decrease in diameter of GV oocytes can be considered as an additional 
parameter to consider when evaluating developmental maturation and 
competence.  
Normality of spindle morphology and chromosome alignment at the 
spindle equator have been used as indicators to assess oocyte quality and 
capability to form chromosomally balanced embryos. Arresting ovarian oocytes 
at the GV stage using PDE3-Is followed by IVM not only maintained normal 
morphology of spindles and alignment of chromosomes at the metaphase plates 
but also synchronized and improved cytoplasmic and meiotic maturation and 
elevated oocyte competence (Albuz et al. 2010 Nogueira et al. 2003a and 
2005b; Vanhoutte et al. 2007 and 2008).  Here, we extend the beneficial effect 
of temporal arrest of oocytes at the GV stage in vitro to the in vivo level and 
have found similar results to those reported in vitro. Although the spindle length 
did not differ among different MI oocytes, the spindle width of MI oocytes 
obtained from IVM of ovarian GV oocytes was greater. Sanfins et al. indicated 
that in vivo matured oocytes from naturally ovulated mice showed a compact 
spindle with focused poles whereas the in vitro matured MI oocytes exhibited a 
barrel-shaped spindle with flat poles (Sanfins et al. 2003). The observed wider 
spindle in our MI oocytes obtained from IVM of ovarian GV oocytes may indicate 
the same phenomenon as oocytes with barreled spindles. 
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In summary, adding to our previous work in which we presented protocols 
for retrieval of ovulated oocytes at different stages of meiotic maturation, we 
here evaluated meiotic and cytoplasmic maturations and fertilization of ovulated 
immature oocytes. We observed that ovulated immature oocytes are at 
advanced meiotic and cytoplasmic maturation levels with organized spindles and 
chromosomes. We also found that GV oocytes are larger than MI oocytes and 
the ovulated immature oocytes are smaller than their ovarian counterparts. We 
therefore suggest that although oocytes of large volumes are correlated with 
high developmental and competence rates, they reduce size as meiosis is 
triggered.  
 
Summary and conclusion 
• Administration of CLZ in superovulated mice results in ovulation of GV 
oocytes with advanced chromatin configuration (SN) when compared to 
ovarian GV oocytes resulting from hyperstimulated mice. 
• Administration of CLZ in superovulated mice resulted in ovulation of GV 
oocytes with advanced cytoplasmic maturation as evidenced by the 
initiation of an intermittent domain of CG instead of the continuous 
peripheral CG noted in ovarian GV oocytes collected from PMSG primed 
mice.  
• Ovulated GV oocytes have an advanced meiotic maturation that is 
merged with their cytoplasmic maturation because SN configuration 
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occurs with both peripheral CG with or without intermittent domain 
whereas no such a trend occurs with ovarian GV oocytes. 
• Ovulated GV oocytes have higher rates of maturation and fertilization 
than ovarian GV oocytes. 
• Ovulated GV oocytes can resume meiosis with shorter periods of time 
than ovarian GV oocytes. 
• Ovulated MI oocytes and MI oocytes resulting from IVM of ovulated GV 
oocytes have higher quality (normal spindle and chromosomal 
organization) than ovarian MI oocytes collected from IVM of ovarian GV 
oocytes. 
• MI oocytes collected from IVM of ovarian GV oocytes have wider spindles 
(a state that occurs in in-vitro matured oocytes more than in vivo matured 
oocytes) than ovulated MI oocytes and MI oocytes obtained from IVM of 
ovulated GV oocytes. 
• Ovulated MI oocytes resulting from administration of CLZ at the same 
time as hCG have significant rates of premature exocytosis of CG. 
• Ovulated GV oocytes are more uniform in diameter than ovarian GV 
oocytes. 
• In vitro matured ovulated GV oocytes have the most uniform size of 
diameters followed by ovulated MI oocytes and finally MI oocytes 
resulting from IVM of ovarian GV oocytes.  
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• Meiosis is associated with size reduction because MI oocytes are smaller 
than GV oocytes, and ovulated GV oocytes that have advanced meiotic 
and cytoplasmic maturation and consequently faster and higher rate of 
maturation and meiosis are smaller than ovarian GV oocytes.  
• Ovulated GV oocytes have smaller GV nuclei than ovarian GV oocytes. 
• Ovulated GV oocytes have greater nucleoli than ovarian GV oocytes. 
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CHAPTER VI 
SYNCHRONIZATION OF OOCYTE MATURATION IN  
SUPEROVULATED MICE IMPROVES IN VITRO FERTILIZATION RATE 
 
Overview 
In vitro synchronization of oocyte nuclear and cytoplasmic maturation has been 
found to improve the IVF rate of in vitro matured ovarian oocytes in comparison 
with non-synchronized corresponding oocytes. Here, we tested the hypothesis 
that synchronization of oocyte maturation in superovulated mice using CLZ 
would increase IVF rates when compared to non-synchronized superovulated 
oocytes. Mice were superovulated (control) to result in ovulation of MII oocytes 
whereas treated mice were superovulated and treated with CLZ to result in 
ovulation of GV or MI oocytes. Ovulated control oocytes were in vitro fertilized 
directly upon collection whereas ovulated MI or GV oocytes were in vitro 
matured followed by IVF. Oocytes from treated mice were collected later to allow 
the ovulated GV or MI oocytes to mature in the oviduct followed by IVF. All 
ovulated MI oocytes that were in vitro or in vivo matured showed higher IVF 
rates than control oocytes. Only ovulated GV oocytes that were in vitro matured 
showed high IVF rates whereas the in vivo matured showed low IVF rates in 
comparison to control oocytes. It is concluded that temporal arrest of oocyte 
maturation during superovulation can increase the IVF rate in mice.  
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Introduction 
The term oocyte cytoplasmic maturation refers to events that occur during two 
distinctive phases of oocyte development. The first phase occurs during follicle 
growth and the second phase occurs during meiotic maturation of the fully grown 
oocyte. Oocyte cytoplasmic maturation during follicle growth includes 
accumulation and storage of maternal mRNA, proteins, substrates, nutrients, 
factors, and their regulatory processes (Gandolfi and Gandofi 2001; Krisher 
2004; Watson 2007). This cytoplasmic maturation phase is essential for early 
embryonic survival, especially before maternal-zygotic gene transition, which is 
around the 2 and 4/8-cell stages in mouse and human embryos, respectively. 
Until embryonic genome activation, the embryo continues to rely on the maternal 
reserve that was produced during cytoplasmic maturation in the growing follicle 
follicle (Bettegowda and Smith 2007; Minami et al. 2007). The higher 
developmental capacity observed in large oocytes compared to small oocytes in 
many species suggests more accumulation of nutrients and transcripts, and 
consequently larger oocyte sizes that efficiently support early embryonic 
development (Marchal et al. 2002; Otoi et al. 2000 and 2001; Raghu et al. 2002; 
Schramm et al. 1993). This cytoplasmic maturation was found to cease as the 
fully grown oocyte of prophase I started to enter meiotic maturation as usually 
evidenced by the lack of fluorescent transcriptional activity around the nucleolus 
of GV oocytes (Bounio-Baly et al. 1999; De La Fuente and Eppig 2001; Tan et 
al. 2009). In addition to the role of the oogenic cytoplasmic maturation in 
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fostering early embryonic development, it is also associated with the 
development of meiosis and embryonic progression post-zygotic gene activation 
(Gandolfi and Gandolfi 2001; Krisher 2004; Minami et al. 2007; Renard et al. 
1994; Watson 2007). 
 Oocyte cytoplasmic maturation during meiotic resumption includes some 
morphological and biochemical events such as CG migration, microfilament 
relocation, MAP kinase phosphorylation, cyclin B synthesis, and p34cdc2 kinase 
activation. The CG distribution was found to migrate to the cortex of oocytes to 
regulate fertilization and prevent polyspermy after fertilization (Barros and 
Yanagimachi 1971; Liu et al. 2005) whereas microfilaments control nuclear and 
CG movement, meiotic spindle rotation, and others (Sun and Schatten 2006). 
Cyclin B, in addition to other kinases and phosphatases, are important for 
p34cdk2 to gain its protein kinase activity (Doree and Hunt 2002; Marangos and 
Carroll 2004; Sun et al. 2001) whereas p34cdc2 kinase activity is essential to GV 
oocyte transition into the MI stage and then to sustain MII arrest until fertilization 
(Choi et al. 1991; Hampl and Eppig 1995). Moreover, MAP kinase was also 
found to associate with arresting oocytes at the MII stage as c-mos (MAP kinase 
kinase kinase) knockout mice resulted in MII oocytes undergoing spontaneous 
parthenogenesis and/or third metaphase (MIII) stage (Carlton 1994, Jones 2004, 
Verlhac et al. 1996).  
The temporal arrest of oocyte meiotic maturation in vitro was reported to 
increase the oocyte cytoplasmic maturation and quality, and consequently IVF 
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and blastocyst rates in several species when compared to non-arrested ovarian 
GV oocytes undergoing spontaneous IVM (Albuz et al. 2010; Nogueira et al. 
2003a and 2005a; Shu et al. 2008; Vanhoutte et al. 2008 and 2007). The 
observed high rates of IVF and blastocysts never exceeded that of ovulated MII 
oocytes. Previously, we found administration of CLZ in vivo resulted in ovulation 
of immature oocytes that have more advanced cytoplasmic and meiotic 
maturation when compared to in vitro matured oocytes that were not arrested 
(Chapter V). Here, we tested the capability of such ovulated immature oocytes to 
resume meiotic maturation in vitro or in vivo. Also, we monitored the in vitro and 
in vivo course of maturation time of these oocytes. We then in vitro fertilized 
those oocytes and observed their 2-cell embryo rates and compared them with 
those resulting from ovulated mature oocytes using a superovulated mouse 
model. 
 
Materials and methods 
 
Mice and superovulation 
 
Swiss Webster mice (8-10 weeks old) were ip injected with 10 IU PMSG at 
6:00pm followed in 47h with 10 IU hCG. All CLZ doses were dissolved in 
aliquots of 0.1ml DMSO just before administration. Control mice received 0.1ml 
DMSO at 7h pre-hCG, 4h pre-hCG, or at 4h pre-hCG and 2h post-hCG. 
Ovulated oocytes from control mice were retrieved 14h post-hCG and underwent 
IVF directly. Ovulated oocytes from treated mice that underwent IVM or oviductal 
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maturation and IVF were incubated in HTF medium supplemented with 4.5% 
FBS at 37°C with 5% CO2in humidified air. Oocyte and spermatozoa collection 
media were HTF supplemented with HEPES and 4.5% FBS. All gonadotropins 
were purchased from Intervet Inc. (Summit, NJ) whereas the culture media were 
obtained from Zenith Biotech (Guilford, CT). CLZ was purchased from LKT 
Laboratories (St. Paul, MN) and all experiments were approved by the Texas 
A&M University Institutional Animal Care and Use Committee.  
 
Experimental design 
Experiments were conducted to test the following hypotheses: 1) Ovulation of MI  
oocytes in superovulated mice treated with 7.5mg CLZ, 7 or 4h pre-hCG, 
followed by maturation for 3 or 6h, respectively, in vitro or in vivo yields IVF rates 
that are higher than those observed in ovulated oocytes collected from 
superovulated mice not treated with CLZ. 2) Ovulation of GV oocytes in 
superovulated mice treated with 7.5mg CLZ, 4h pre-hCG and 2h post-hCG, 
followed by IVM or in vivo maturation (IVOM) for 10h yields IVF rates that are 
higher than those observed in ovulated oocytes collected from superovulated 
mice not treated with CLZ. Figure 6.1 shows the experimental design for testing 
these hypotheses. 
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Figure 6.1. The experimental design of chapter six. Ovulated germinal vesicle (GV) and 
metaphase I (MI) oocytes were in vitro or in vivo matured (IVM or IVOM, respectively) to mature 
oocytes followed by in vitro fertilization (IVF) from superovulated mice; pregnant mare serum 
gonadotropin (PMSG) and human chorionic gonadotropin (47h apart). Cilostazol (CLZ) was 
administered in the treated group at the designated times.  
 
 
 
Mice treated with 7.5mg CLZ at 7h or 4h pre-hCG 
To study the capability of ovulated MI oocytes to undergo in vitro or in vivo (in 
the oviduct) maturation and IVF, mice were treated with 7.5mg CLZ, 7h pre-
hCG, and were divided into two groups. For the first group, oocytes were 
retrieved 14h post-hCG (8:00am) and then in vitro matured for 3h (until 
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11:00am). For the second group, oocytes were retrieved 17h post-hCG 
(11:00am). Oocytes from both groups were denuded in 0.006% hyaluronidase 
for 2 minutes and scored for their maturational status using a Nikon SMZ1500 
stereomicroscope and an Olympus IX71 inverted microscope. In the following 
experiments, the superovulated treated mice were sacrificed and the ovulated 
CEO underwent IVM or IVOM as described followed by IVF (using the same 
semen suspension) without denudation at 11:00am. All oocytes were then 
incubated for 1 day and scored for the 2-cell embryo endpoint.  
Other mice were treated with 7.5mg CLZ, 4h pre-hCG, and were divided 
into two groups. Ovulated oocytes from the first group were retrieved 14h post-
hCG and in vitro matured for 6h (up to 2:00pm). For the second group, oocytes 
were retrieved 20h post-hCG (2:00pm). Oocytes from both groups were then 
denuded and scored for their maturational status or underwent IVF without 
denudation as described above.  
 
Mice treated with 7.5mg CLZ at 4h pre-hCG and 2h post-hCG 
To study the capability of ovulated GV oocytes to undergo in vitro or in vivo 
maturation and IVF, mice were treated with 7.5mg CLZ, 4h pre-hCG and 2h 
post-hCG, and were divided into two groups. For the first group, oocytes were 
retrieved 14h post-hCG and in vitro matured for 10h (up to 6:00pm). For the 
second group, oocytes were retrieved 24h post-hCG (6:00pm). All oocytes were 
then denuded and scored for their maturational status. In another experiment, 
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the superovulated treated mice were sacrificed and ovulated oocytes were 
collected and underwent IVM or IVOM as described, followed by IVF (using the 
same semen sample) without denudation at 6:00pm. All oocytes were scored 1 
day after IVF for the 2-cell embryo endpoint.  
 
In vitro fertilization 
The tails of the epidiymides attached to the ductus deferens were placed in 
1.5ml HTF medium with HEPES. The ductus deferens attached to the posterior 
thick tubule of the epididymis was separated followed by flushing with the HTF 
medium using a 26 gauge blunted needle. A few cuts were made in the 
remaining epididymis tail to allow more spermatozoa to swim out. The 
spermatozoa suspension was incubated for 10-15 minutes for capacitation.  
Concentrations of 2 million spermatozoa/ml were prepared in the medium 
containing oocytes collected from three females. Oocytes were incubated with 
spermatozoa for 6h followed by three washes and incubated for one day.  
 
Results 
We previously showed that CLZ administered 7 or 4h pre-hCG in superovulated 
mice resulted in ovulation of more than 90% MI oocytes. Moreover, we observed 
that the ovulated MI oocytes resulting mice treated with 7.5mg CLZ, 7h pre-hCG, 
were semi-MII oocytes as evidences by the presence of membranous 
protrusions indicating the imminent extrusion of the 1st polar body (Chapter III). 
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Here, we found that delaying retrieval of such ovulated MI oocytes (semi-MII 
oocytes) to 17h post-hCG (11:00am) or retrieving the oocytes 14h post-hCG 
(8:00am) followed by IVM until 11:00am allowed all of these MI oocytes to finish 
meiotic maturation with a yield of MII oocytes that was similar to that in control 
mice. In the following experiments, MII oocytes resulting from IVM or IVOM of 
those ovulated MI oocytes were in vitro fertilized 17h post-hCG without 
denudation because of the importance of the cumulus cells for fertilization and 
embryonic development. Both in vivo and in vitro matured MI oocytes from mice 
treated with 7.5mg CLZ at 7h pre-hCG showed higher rates of 2 cell embryo 
production when compared to ovulated MII oocytes from control superovulated 
mice (90.6% and 88.2% vs. 81.5%, P<0.0001 and P=0.017, respectively, Fig. 
6.2). 
Scoring of the ovulated MI oocytes 20h post-hCG (2:00pm) from mice 
treated with 7.5mg CLZ, 4h pre-hCG, showed oocytes at the MII stage whether 
matured in vitro or in vivo (in the oviduct). For those oocytes, IVM or IVOM 
followed by IVF without denudation 20h post-hCG resulted in high rates of 2-cell 
embryos when compared to the IVF rate observed in ovulated MII oocytes from 
control mice (89% and 87.8% vs. 80.2%, P=0.007 and P=0.014, respectively, 
Fig. 6.3).  
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Here, we found that scoring of the ovulated GV oocytes that underwent 
IVM for 10h revealed a yield of MII oocytes that was similar to that observed in 
control mice. On the other hand, GV oocytes retrieved from oviducts 24h post-
hCG (6:00pm) also resulted in a similar yield of MII oocytes to that observed in 
Figure 6.2. Two cell embryo rates for ovulated MI oocytes resulting from Mice treated with 
7.5mg CLZ at 7h pre-hCG. Ovulated MI oocytes were collected 14h post-hCG followed by  
IVM for 3h and IVF or at 17h post-hCG (IVOM) followed by IVF. Oocytes from control mice 
were collected 14h post-hCG and underwent IVF. IVM: in vitro maturation; IVOM: in vivo 
maturation. Number inside each bar is the total number of oocytes evaluated. *<0.1 and 
****<0.0001.  
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control mice but some of those MII oocytes were degenerated; fragmented 
(P=0.01). 
 
 
 
 
 
 
 
 
 
The in vitro matured ovulated GV oocytes showed a higher IVF rate than 
that of control MII oocytes (95.2% vs. 89.4%, P=0.013) but the in vivo matured 
(oviductal matured) oocytes had a lower rate of cleavage (73.5%) in comparison 
Figure 6.3. Two cell embryo rates for ovulated MI oocytes resulting from Mice 
treated with 7.5mg CLZ at 4h pre-hCG. Ovulated MI oocytes were collected 14h 
post-hCG followed by IVM for 6h and IVF or at 20h post-hCG (IVOM) followed by 
IVF. Oocytes from control mice were collected 14h post-hCG and underwent 
IVF.IVM: in vitro maturation; IVOM: in vivo maturation. Number inside each bar is 
the total number of oocytes evaluated. *<0.05 and **<0.01. 
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to control MII oocytes and in vitro matured GV oocytes (P<0.0001, Fig. 6.4). To 
exclude the effect of degenerated MII oocytes on this low fertilization rate, the in 
vivo matured GV oocytes were denuded just before IVF, and the degenerated 
oocytes were removed before IVF. Control ovulated MII oocytes were also 
denuded before conducting IVF to control for the denudation effect on 
fertilization. At 24h post-fertilization of the denuded oocytes, the in vivo matured  
 
 
 
 
Figure 6.4. Two cell embryo rates for ovulated GV oocytes resulting from Mice treated with 
7.5mg CLZ at 4h pre-hCG and 2h post-hCG. Ovulated GV oocytes were collected 14h post-hCG 
followed by IVM for 10h and IVF or at 24h post-hCG (IVOM) followed by IVF. Oocytes from 
control mice were collected 14h post-hCG and underwent IVF.IVM: in vitro maturation; IVOM: in 
vivo maturation. Number inside each bar is the total number of oocytes evaluated. *<0.05 and 
****<0.01. 
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GV oocytes continued to show low 2-cell embryo rates when compared to the 
control oocytes (P<0.0001, Fig. 6.5). The degeneration noted with control 
denuded oocytes that underwent IVF was higher than that of in vivo GV matured 
denuded oocytes but was not statistically significant (9.5% vs. 4.7%, P=0.05). 
 
 
 
Figure 6.5. Normality and fertilization rates of GV oocytes in vivo matured in the oviduct. Mice 
were treated with 7.5mg CLZ at 4h pre-hCG and 2h post-hCG and oocytes were collected 24h 
post-hCG (IVOM). The oocytes were denuded and scored according to their normality with MII 
ovulated oocytes collected from control mice 14h post-hCG (A). The normally scored MII oocytes 
(denuded) obtained from IVOM were in vitro fertilized and compared to control MII oocytes that 
were also denuded (B).  
 
 
 138 
 
Discussion 
We observed here that ovulated MI oocytes from superovulated mice treated 
with CLZ can resume meiotic maturation in the oviduct or in vitro and that the 
resulting MII oocytes had maturation rates similar to those observed in untreated 
superovulated mice.  Such oviductal or in vitro matured MI (into MII) oocytes 
have, upon IVF, high rates of 2-cell embryos when compared to those of 
ovulated MII oocytes from control mice. We then studied the IVF outcomes from 
ovulated GV oocytes and found that the GV oocytes were also capable of 
resuming meiotic maturation in the oviduct or in vitro and to yield MII oocytes at 
normal rates. Such MII oocytes exhibited higher IVF rates when the GV oocytes 
underwent IVM than that of control ovulated MII oocytes but the MII oocytes 
resulting from the oviductal maturation of GV oocytes had lower IVF rates. We 
observed that oviductal maturation of ovulated GV oocytes was associated with 
low rates of normal MII oocytes. Moreover, conducting IVF on only those 
normally scored MII oocytes continued to show lower rates of 2-cell embryos. 
We found that the administration of CLZ in superovulated mice was not only able 
to increase the IVF rate but also to synchronize meiotic maturation progression 
among oocytes and to synchronize maturational course time between IVM and 
IVOM of immature oocytes.  
Scoring of ovulated GV oocytes matured in vivo or in vitro after 10h 
showed approximately 100% MII oocytes whereas GVBD was observed to occur 
around 1h in vivo or in vitro (Chapter III and IV). Conversely, scoring oocyte 
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maturation in superovulated mice not treated with CLZ showed emission of the 
1st polar body as early as 6h post-hCG whereas occurrence of GVBD was first 
observed 3h post-hCG and continued to occur up to 9h post-hCG; the last time 
point tested in this mouse species (Chapter III). Also monitoring of IVM of 
ovarian GV oocytes showed MII maturation rate of 61.6% after 10h that 
continued to increase up to 14h in this mouse strain. These results show that 
temporal arrest of meiosis during superovulation is capable of synchronizing 
GVBD and 1st polar body emission in a uniform meiotic progression among 
oocytes in comparison to those observed in oocytes that have not been 
temporary arrested. This also directs attention to the occurrence of early polar 
body emission, and consequently ovulation of aged MII oocytes with 
compromised viability, quality, and fertility. This emphasizes the usefulness of 
synchronization of oocyte maturation in superovulation programs.  
Furthermore, CLZ allowed for both in vitro and in vivo maturation of 
oocytes to be synchronized. Here, we observed similar in vitro and in vivo 
maturation periods of 3 or 6h for MI oocytes; depending on CLZ time of 
administration, and 10h for GV oocytes. Conversely, IVM of oocytes upon 
release from the follicle is about 14-18h in most mouse strains whereas in vivo 
maturation of oocytes in superovulated mice requires 12-13h; the time window 
between the ovulatory stimulus and ovulation. In fact, it is not only the timing of 
the 1st polar body emission that is different between in vitro and in vivo matured 
oocytes but also GVBD. While timing of GVBD in oocytes undergoing IVOM was 
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reported to be greatly varied from 1h to 8h post-hCG, depending on mouse 
strain, GVBD under IVM is found to be within 3h (Calarco et al. 1972; Chapters 
III and V; Edwards and Gates 1959; Hsieh et al. 2007; Kalous et al. 2006; Miao 
et al. 2004).  
Administration of a PDE3-I in superovulated mice blocks meiotic 
maturation at the GV stage, allowing more oocytes to synthesis and to 
accumulate the necessary transcripts, proteins, and nutrients that aid in 
sustaining meiotic progression and foster early embryonic development (Krisher 
2004; Watson 2007). This temporal arrest at the GV stage was also observed to 
allow oocytes to gain an advanced chromatin configuration of SN. Administration 
of gonadotropins in superovulated mice are known to increase SN configuration 
in oocytes but administration of CLZ in superovulated mice is believed to have a 
synergistic effect on having SN configuration in oocytes since intraoocyte cAMP 
was found to positively correlate with SN configurations in oocyte (Bouniol Baly 
et al. 1999; chapter V; de Lesegno et al. 2009; Nogueira et al., 2003a; 
Vanhoutte et al. 2007; Zuccotti et al. 1998 and 2002). In addition to SN 
configuration, superovulated mice treated with CLZ have oocytes with advanced 
cytoplasmic maturation of CG with intermittent domain (CGID), a pattern that 
precedes the formation of free domain in the peripheral CG pattern in MI 
oocytes. As a result, such oocytes that had more time to finish RNA synthesis, 
gain SN configuration, and display advanced CG distribution were found to yield 
higher rates of IVF than control ovulated MII oocytes.  
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Superovulation in mice was found to cause a delay in embryonic 
development, an increase in abnormal blastocyst formation, and pronounced 
fetal growth retardation (Van der Auwera and D`Hooghe 2001). Superovulation 
in hamster was reported to cause abnormal microfilament distribution and to 
adversely affect embryonic development (Lee et al. 2005). Moreover, a dose-
response relationship between PMSG dose and the incidence of polyploidy was 
noted (Ma et al. 1997). In human superovulation, serial measurements of serum 
estrogen and applications of transvaginal ultrasonography are used to monitor 
the follicular development and to adjust hormonal dosage administrations (Tur et 
al. 2001). Nevertheless, a delay of embryonic development and low birth weights 
were also observed after IVF in humans (FIVNAT 1995; Sundstrom et al. 1997). 
It is suggested that the exogenous gonadotropins have a negative impact on 
oocyte maturation and consequently fertilization in addition to the observed 
effect of lack of synchronization of meiotic progression among oocytes.  
Administering CLZ in superovulation is believed to reduce some of these 
adverse effects since temporal arrest of meiosis is positively correlated with SN 
configuration, transcript and substrate accumulation, advanced CG distribution, 
and synchronization of meiotic events among oocytes (Chapter V).   
Previous reports showed that in vitro arrest of oocytes at the GV stage 
using PDE-I was associated with higher oocyte quality, fertilization rate, and 
embryonic development when compared to those of non-arrested GV oocytes 
but lower than those of ovulated MII oocytes (Albuz et al. 2010; Nogueira et al. 
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2003a; Shu. et al. 2008; Vanhoutte et al. 2007 and 2008). This indicates the 
superiority of in vivo maturation and the beneficial effect of temporal arrest of 
meiotic maturation. On the other hand, other investigators have reported the lack 
of such beneficial effects on oocyte maturation and IVF rate (Curnow et al. 2011; 
Jee et al. 2009). It is possible that the concentration, the PDE3-I type, and/or the 
duration of arresting of oocytes at the GV stage are the factors that explain such 
discrepancies. While the in vivo arrest of oocytes at the GV stage followed by 
IVM improved the IVF rate more than that of ovulated MII or in vitro matured 
ovarian GV oocytes (Chapter V), the ovulated GV oocytes matured in vivo 
resulted in the lowest IVF rate because of the high degeneration rate and poor 
fertilization capability. Interestingly, oviductal maturation of MI oocytes for 3 or 
6h in mice treated with a single CLZ dose showed no such degeneration or poor 
IVF rate. In humans, delaying IVF after oocyte collection resulted in high levels 
of fertilization, fetal development, and pregnancy (Patrat et al. 2012; Sundstrom 
and Nilsson 1988; Trounson et al. 1982). Moreover, delaying oocyte retrieval 
after the hCG injection showed similar results (Son et al. 2008). These results 
indicate that prolonged in vivo/vitro maturation of oocytes is beneficial and may 
increase cytoplasmic maturation. In our study, the incubation period for the 
oviductal maturation was similar to the duration of IVM, excluding the possibility 
of factor(s) undergoing aging in oocytes upon prolonged meiotic arrest and 
maturation. Therefore, it is suggested that other in vivo factor(s) such as CLZ 
 143 
 
concentration upon multiple administrations may affect oocyte viability and 
normality.   
CLZ has an elimination half life of 11-13h in humans, which is thought to 
be relatively similar to that of mice (Chapter III and IV).  The compound also has 
active metabolites and high protein binding capacity of 95–98% (Lacy et al. 
2011). Although delaying retrieval of GV oocytes in mice treated with 7.5mg 
CLZ, 4h pre-hCG and 2h post-hCG, resulted in mice ovulating mostly MI 
oocytes, only half of the mice treated with 7.5mg CLZ at the same time of hCG 
and 6h post-hCG yielded mostly MI oocytes upon delayed retrieval (Chapter III). 
Genetic polymorphisms in hepatic CYP 450; CYP3A (CYP3A5*3) and CYP2C19 
(CYP2C19*2 and CYP2C19*3), were found to cause substantial interindividual 
variability in CLZ clearance when administered orally (Yoo et al. 2010). 
Moreover, sex differences were also reported to affect pharmacokinetics of CLZ 
in rats (Kamada et al. 2011). It is possible that not all mice treated with multiple 
CLZ administrations could show similar CLZ metabolic profiles and consequently 
CLZ inhibitory concentrations could be maintained longer in some of the treated 
mice. As a result, the meiotic maturation kinetics may be disrupted. Another 
possibility for the poor oocyte fertilization potential of MII oocytes resulting from 
IVOM of ovulated GV oocytes is the observed ovulated GV oocytes with high 
rates of peripheral CGID whereas some of the ovulated MI oocytes had been 
reported to have exocytosed CG (Chapter V). The exocytosed CG status was 
reported to occur in fertilized, aged, or apoptotic oocytes whereas the CGID is a 
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transition feature between GV oocytes that mature to MI oocytes (Chapter V; Liu 
et al. 2003 and 2005). Moreover, it was reported that arresting oocytes at the GV 
stage by delaying the endogenous LH for one day in rats is associated with 
abnormal distribution of CG resulting in decreases in oocyte fertility and litter 
size (Stoker et al. 2003). It is possible that early activation or abnormality of CG 
is responsible of such low fertilization capacity. Those two factors; CLZ 
metabolic profile and premature CG activation, discussed here may explain the 
compromised fertilization rate in normal MII oocytes obtained from IVOM of GV 
oocytes but not the observed high rate of degeneration in the matured MII 
oocytes.  
CLZ was reported to have cellular protective properties against reactive 
oxygen species and DNA fragmentation. The compound inhibits oxidative stress, 
augments metallothionein, and restores reduced glutathione levels (Lee et al. 
2004 and 2010; Ota et al. 2008; Shin et al. 2004; Suzuki et al. 2007). 
Nevertheless, potential degenerative impact of CLZ or its metabolites could be 
the reason behind the notable degeneration in MII oocytes resulting from IVOM 
of GV oocytes. Prolonged maintenance of ovarian oocytes at the GV stage in 
vitro is harmful and leads to degeneration. Moreover, this degeneration 
increased as the CLZ concentration and incubation time increased. A sustained 
high intraoocyte cAMP level is suggested to be positively correlated with oocyte 
degeneration (Chapter II). The longer arrest of oocytes at the GV stage in the 
oviduct than that in vitro is likely if some of the CLZ treated mice had had 
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different CLZ pharmacokinetics resulted from poor metabolizing enzymes (as 
discussed in the previous section). It is believed that prolonged arrest of oocytes 
at the GV stage in vivo increases degeneration.   
In addition to the synchronization of oocyte meiotic and cytoplasmic 
maturation and its positive consequences, it is observed in this study that 
synchronization of meiotic progression among oocytes in vitro or in vivo is 
possible. Moreover, both in vitro and in vivo maturation course times of 
immature oocytes were also synchronized. Consequently, ovulated GV or MI 
oocytes were fertilized and resulted in higher rates of 2-cell embryos than those 
of ovulated MII oocytes except for GV oocytes when they resumed meiosis in 
vivo. If CLZ is capable of showing the same meiotic inhibition in other species, 
such a technique may be adopted in IVF clinics to increase pregnancy rates. 
Nevertheless, further evaluation of this technique should address the entire 
oocyte competence including production of blastocysts, live births, and 
epigenetic effects.   
 
Summary and conclusion 
• Ovulated MI oocytes resulting from superovulated mice treated with 
7.5mg CLZ, 7h pre-hCG, have similar maturation rates but higher IVF 
rates, upon in vitro or in vivo maturation, than ovulated MII oocytes 
resulting from superovulated mice not treated with CLZ.  
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• Ovulated MI oocytes resulting from superovulated mice treated with 
7.5mg CLZ, 4h pre-hCG, have similar maturation rates but higher IVF 
rates, upon in vitro or in vivo maturation, than ovulated MII oocytes 
resulting from superovulated mice not treated with CLZ.  
• Ovulated GV oocytes resulting from superovulated mice treated with 
7.5mg CLZ administered at the same time as hCG and 6h post-hCG have 
similar maturation rates but higher IVF rates, upon in vitro maturation, 
than ovulated MII oocytes resulting from superovulated mice not treated 
with CLZ.  
• Ovulated GV oocytes resulting from superovulated mice treated with 
7.5mg CLZ administered at the same time as hCG and 6h post-hCG have 
similar maturation rates but with higher degeneration rates, upon in vivo 
maturation, than ovulated MII oocytes resulting from superovulated mice 
not treated with CLZ. 
• Meiotic maturation of ovulated MI oocytes resulting from CLZ 
administered 4 or 7h pre-hCG or GV oocytes resulting from CLZ 
administered at the same time as hCG and 6h post-hCG can be 
synchronized to mature within the same time. Scoring the maturation 
state for those immature oocytes after 3, 6, or 10h, respectively, revealed 
that all oocytes matured into the MII stage.  
• In vitro and in vivo meiotic maturation of ovulated MI oocytes, resulting 
from CLZ administered 4 or 7h pre-hCG, or GV oocytes, resulting from 
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CLZ administered at the same time as hCG and 6h post-hCG, can be 
synchronized to occur at a similar time. Scoring maturation status for 
those immature oocytes after 3, 6, or 10h, respectively, revealed that all 
oocytes matured into the MII stage whether oocytes were matured in vitro 
or in vivo.  
• In addition to the high degeneration rate associated with MII oocytes 
resulting from in vivo maturation of ovulated GV oocytes, the non-
degenerated MII oocytes also have poor fertilization capability.  
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CHAPTER VII 
CONCLUSION 
 
The contraceptive properties of CLZ were evaluated using mice. We 
found that CLZ is able to arrest spontaneous oocyte maturation in vitro, to inhibit 
oocyte maturation in superovulated mice with a wide range of times of 
administration, and to block pregnancy in naturally cycling mice.  
Ovulated immature oocytes obtained from superovulated mice treated 
with CLZ were evaluated by comparing them with ovarian immature oocytes 
obtained from hyperstimulated mice and with ovulated mature oocytes obtained 
from superovulated mice not treated with CLZ. We concluded that the ovulated 
immature oocytes have an advanced cytoplasmic and meiotic maturation and 
higher fertilization rates (2-cell embryo) when compared to both ovarian 
immature and ovulated mature oocytes. We also concluded that synchronization 
of meiotic progression among oocytes or between in vitro and in vivo matured 
oocytes in superovulated mice is achievable when CLZ is administered.  
During this study, we formulated the principle that CLZ is not only able to 
block oocyte meiotic maturation and pregnancy but also can be utilized to 
produce oocytes with high developmental levels and fertilization rates. From the 
contraceptive point of view, CLZ merits further evaluation as a potential non-
steroidal contraceptive. From the higher developmental and fertilization point of 
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view, administration of CLZ in superovulation protocols merits continued 
investigation to address oocyte competence comprehensively .  
Future studies are required to evaluate CLZ contraceptive effects in other 
animal models. Studies are also needed to address the different 
pharmacological responses of CLZ between mice and rats. Administration of 
CLZ in rats using the described method of administration in this study and/or 
administration of CLZ in mice using the manufacturer`s method of administration 
will aid to uncover the differences between mice and rats and the differences 
between the different methods of administration. Finally, comprehensive 
evaluation for the CLZ ability to improve oocyte quality and fertilization requires 
producing live offspring and evaluating their normality.   
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